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1 - Introduction 
 
1. Introduction 
 
Understanding the mechanisms of pathogenesis means having a glimpse into the 
hundreds of millions of years of common evolution between the various 
organisms existing on this planet. While most prominent pathogens elicit acute 
diseases, which we understandably feel and fear most, they are probably only 
short-lived sparks in the evolutionary timeline. They represent extreme 
situations, not well reflecting the massively parallel evolutionary optimization 
processes discreetly accompanying us in a hidden network of viruses, prions, 
catalytic RNAs, bacteria, plants and animals. As we discover and describe more 
and more highly adapted organisms being intimately involved and entangled in 
our lifestyles, behaviors and our own evolutionary success, the classical, 
restrained definition of species might well be outlived. Elucidating the molecular 
mechanisms these highly adapted organisms use to associate themselves to 
others will have a deep impact on our understanding of biology. 
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1.1  Signaling by means of phosphotyrosines 
 
One of the most important means of controlling, regulating and computing 
communication in a complex system is to use reversible switches. This permits a 
much greater complexity without increasing the actual number or types of 
objects involved.  Such a molecular switch, regulating many functions in and 
between the proteins it is present, is the phosphorylation of tyrosine residues. 
Proteins catalyzing the addition of a phosphate group to tyrosines are known as 
tyrosine kinases, the ones removing it as tyrosine phosphatases (1).  In the late 
1970’s, viral oncogenes such as v-Src, v-Abl and v-Fbs were discovered whose 
products had an intrinsic activity in phosphorylating tyrosine residues in 
proteins (2-5). Their precursors and cellular counterparts (c-Src, c-Abl, etc…), as 
well some surface receptors binding growth factors were also shown to contain 
such an activity (6, 7). Hoping to understand more about the cell signaling and 
the oncogenic mechanisms used by these proteins, a very fruitful quest was 
started to unravel the underlying machinery of these covalent modifications. The 
knowledge accumulated the last 35 years concerning this modification and its 
manifold effects in the cell highlights its immense importance in the regulation of 
eukaryotic cells. 
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1.1.1  The Src Family Kinases and Csk 
 
Tyrosine kinases are present either in the form of receptors anchored into the 
membrane with an intracellular kinase activity, the receptor tyrosine kinases 
(RTK), or as soluble forms, being facultatively anchored of tethered to the 
membrane or to signaling complexes (8, 9).  The Src Family Kinases (SFKs) got 
their name for its best studied and prominent member, c-Src, and encompasses 
eight proteins in mammals (c-Src, Lyn, Yes, Fyn, Lck, Hck, Fgr, and Blk). They all 
contain an N-terminal fatty acylation site, a unique domain, where they are most 
divergent between the different members of the SFKs, a polyproline binding SH3 
domain, an SH2 domain, a kinase domain and a C-terminal tail. 
SFKs are potent activators of signaling pathways as illustrated by their 
prominent role as oncogenes and need therefore to be tightly regulated. While 
phosphatases undo the tyrosine-phosphorylation caused by the kinases, a more 
economical way is to regulate the activity of the SFKs themselves.  Most of the 
work in unriddling the regulation of the SFKs has been achieved by studying Src. 
The transforming v-Src has enhanced kinase activity in comparison to c-Src. 
Intriguingly, v-Src lacking Y527 was shown to be mainly tyrosine-phosphorylated 
on Y416, whereas c-Src is mainly tyrosine-phosphorylated on Y527  (10).  This led 
to the notion that Y416 activates, and Y527 inhibits the kinase activity of c-Src 
(11). Y416 was later identified as an autophosphorylation site and Y527 as being 
phosphorylated by the C-terminal Src kinase (Csk) (12). Further studies showed 
the SH2 domain of c-Src having a low affinity for Y527, which, when 
phosphorylated, forms a loop with the domain and inhibits the kinase activity. 
The solved structure of c-Src and Hck completed the picture (13, 14). In its 
inactive form, the SH2 domain of Src interacts with its C-terminal 
phosphotyrosine-527, while the SH3 domain binds to a short polyproline motif 
between the kinase and the SH2 domain. These two intracellular loops close the 
protein an render it inactive. 
 Csk is a potent inhibitor of the SFKs. It is ubiquitously expressed, notably in 
hematopoietic cells.  The modular structure of Csk is very similar to the one of 
the SFKs. The main differences are the lack of the N-terminal unique sequence 
including the acylation site, and a lack of both regulatory tyrosines present in the 
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SFKs. This raised some fundamental questions concerning the regulation of its 
activity. The lack of an acylation site at the N-terminus suggests that Csk is 
mainly present in the cytoplasm, and must somehow be recruited to the 
membrane-associated SFKs to exert its function. This relocalization was shown 
to be mediated by proteins interacting with the SH2 or SH3 domains of Csk, as 
for example the Csk-binding protein/phosphoprotein associated with 
glycosphingolipid-enriched microdomains (Cbp/PAG). Cbp/PAG is associated to 
lipid rafts in the membrane (15, 16) and is phosphorylated on Y314 by activated 
SFKs. Following phosphorylation of this residue, Csk is recruited to the 
membrane to bind Cbp/PAG on Y314, by virtue of its SH2 domain. Additionally, 
the binding of its SH2 domain fully activates Csk, enabling it to down regulate 
the activity of the SFKs present at the membrane by phosphorylating their C-
terminal inhibitory tyrosine. This straightforward feedback loop is thought to 
enable the cell to keep the amount of activated SFKs under control.   
 
1.1.2  The SH2 domain 
 
The SH2 domain can be considered as the prototypical domain for modular cell 
signaling. It was initially discovered in the retroviral protein tyrosine kinase v-
Fps as non-catalytical domain which altered the localization and the kinase 
activity of this protein (17). Subsequently, a similarly localized sequence of about 
100 amino acids was discovered in the tyrosine kinases Src and Abl, and termed 
SH2 (for Src Homology domain 2), with SH1 being already used to delineate the 
kinase domain (18).  This suggested (i) that the kinase has a modular 
organisation (ii) that target specificity is not mediated by the kinase domain 
alone. 
The idea of a modular organization for many proteins involved in cell signaling 
was further supported by the discovery of v-Crk, and its cellular counterpart c-
Crk. This protein contains an SH2 domain and additionally a then newly 
described SH3 domain (19), which was later shown to bind to polyprolines (20). 
V-Crk enhances tyrosine-phosphorylation of cellular proteins without encoding a 
kinase domain. This finding supported the possibility of Crk recruiting kinases to 
form a complex encompassing multiple proteins. 
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The association of SH2 domain-containing proteins such as the phospholipase C 
(PLCγ) to activated and therefore tyrosine-phosphorylated RTKs finally led to the 
notion that this domain could bind phosphotyrosines. Single isolated SH2 
domains from PLCγ were shown to bind to a variety of tyrosine-phosphorylated 
proteins, proving that an SH2 domain is sufficient for this binding (21). Finally, 
studies using phosphopeptides identical to the putative binding sites of SH2 
domains in the C-terminus of RTKs demonstrated that these peptides bind to the 
domain in a tyrosine-phosphorylation dependent manner (22, 23). 
Binding analyses in vitro and in vivo highlighted that the SH2 domain 
specifically recognizes the phosphorylated tyrosine and the amino acids located 
to the immediate C-terminus of it.  This concept was used in a hallmark screen 
where a large library containing peptides with a phosphotyrosine and 
degenerated flanking amino acids was screened with different SH2 domains, 
discovering the importance of the positions +1 and +3 C-terminally to the 
phosphotyrosine (24). The relatively modest dissociation constant of 500-1000 
nM for the SH2-phosphotyrosine-containing peptide interaction supports its 
dynamic nature (25). Structural analysis of SH2 domains binding their cognate 
phosphorylated peptides showed that their common fold are two α-helices 
surrounding an antiparallel β-sheet with the phosphorylated tyrosine embedded 
in a positively charged pocket in the β-sheet  (26). 
An SH2 domain is often capable of associating to multiple phosphotyrosine 
containing sequences in different proteins and the reverse is also true. A certain 
phosphopeptide ligand may bind several different SH2 domains with various 
affinities, enabling cells to build complex and dynamic interaction networks (27).  
Most proteins contain in addition to the SH2 domain multiple other domains 
with functions as various as binding (SH3, PTB), enzymatic activity (kinases, 
phosphatases, GTP-exchange factors), and transcription factors (STAT), 
supporting the notion of the modularity of cell signaling. 
1.1.3  The PTB domain 
 
The phosphotyrosine binding (PTB) domain was first recognized in the Shc 
scaffold protein by screening expression libraries for proteins binding the 
intracellular, tyrosine-phosphorylated domain of the EGF-receptor. Remarkably, 
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although an intraction with Shc could be expected because of its SH2 domain, 
fragments lacking the SH2 domain were recovered, which indicated that another 
domain than SH2 in Shc could bind to phosphotyrosines (28, 29). Further work 
elucidated this domain in Shc to be about 200 amino acids in size, and to 
associate to the Asn-Pro-X-pTyr motif in activated RTKs. As more proteins 
containing PTB domains were described, it became clear that this domain was 
much less strictly defined as the SH2. Surprisingly, a phosphorylated tyrosine is 
by no means a necessity, as many motifs without it are recognized and bound by 
PTB domains (30).  Structural analysis of seven PTB domains showed their 
common structure being a pleckstrin-homology superfold (31), which differs 
from the SH2-fold structure. This suggests separate evolutionary developments 
between the SH2 and the PTB domains. Although of great importance in cell 
signaling, the variety of ligands binding in many different ways to the PTB 
domains are a considerable challenge in studying this domain, and led to the 
notion that PTB stands for “Promiscuous, Tolerant and Bizarre” (31). 
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1.1.4  SHP1 and SHP2  
 
The catalysts to remove of a phosphate group from a tyrosine are known as 
tyrosine phosphatases (1). As with the tyrosine kinases, they come in two flavors. 
Either as receptors anchored to the membrane, the receptor protein tyrosine 
phosphatases (RPTP) or as facultatively soluble, non-transmembrane forms, 
which will be discussed here (32).  SHP2, encoded by the gene PTPN11, contains 
two SH2 domains in its N-terminus, followed by a phosphatase domain and a C-
terminal tail. In its inhibited state, a loop of the N-terminal SH2 domain binds to 
the phosphatase domain and prevents it from being active. The more C-terminal 
SH2 domain is free and can mediate the binding to a first phosphotyrosine-
containing motif of an interaction partner. This causes a relocalization and then 
facilitates the binding of the N-terminal SH2 domain to the second 
phosphotyrosine motif, thereby freeing and activating the phosphatase domain 
(33). Deletion of exon 3 of murine SHP2 leads to defects in gastrulation, 
lymphopoeisis, heart development, and to embryonic lethality (34). Mutations in 
the PTPN11 gene are associated in humans with the Noonan and Leopard 
Syndrome,  autosomal-dominant disorders leading to a multitude of 
developmental defects (35, 36).  
While the tyrosine phosphatase function of SHP2 is well defined, the manner in 
which it influences the signaling is quite complex (34, 37). Dominant-negative 
phosphatase dead SHP2 inhibits the activation of the Ras-Erk pathway mediating 
the cellular response for many cytokine receptors, suggesting a positive signaling 
for SHP2 in these cascades upstream of Ras  (38, 39). An explanation for this 
positive signaling of SHP2 was published in 2004 (40), where Zhang et al. 
showed that growth factor-evoked SFK activation required SHP2 activity. By 
dephosphorylating Cbp/PAG, SHP2 inhibits the localization of Csk to the plasma 
membrane; subsequently, the tyrosine phosphorylation of the SFKs by Csk on 
their inhibitory tyrosine is reduced. By indirectly influencing the activity of the 
SFKs in a positive manner, SHP2 might therefore govern the wide variety of 
pathways that are controlled by the SFKs. SHP2 has also been associated to 
negative signaling in the JAK-STAT pathway, where data indicate that JAK1 is a 
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direct substrate of SHP2 (41). These findings lead to the conclusion that SHP2 
can act both in an activatory and in an inhibitory way. 
SHP1, encoded by PTPN6, is predominantly expressed in hematopoietic cells, 
where it down-regulates signaling of transmembrane receptors as various as 
cytokine receptors, growth factor receptors with an intrinsic tyrosine-
phosphorylation activity, and receptors involved in immune signaling (42). Its 
crystal structure suggests the same type of regulation as SHP2, with the N-
terminal SH2 domain blocking the phosphatase domain in its deactivated state 
and the more flexible C-terminal SH2 being involved in scanning for potential 
binding partners. Mice with defects in SHP1 expression, termed the motheaten 
mice, exhibit severe developmental abnormalities in many hemopoeitic lineages 
and die approximately three weeks after birth (43).   
A further prominent role for SHP1 and SHP2 is their association to the inhibitory 
receptors of the immune system, which is discussed in the next chapter. 
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1.2  Immune Receptors 
 
The immune system faces the challenge of having to be extremely reactive 
against pathogens, pathogen-infected and malignant cells, some of which it has 
never encountered before, and, at the same time, tolerate the many cell types and 
processes normally occurring in an organism. This balance is achieved by 
regulation networks influencing positively and negatively the activation of the 
immune cells.  
Whereas the activation and suppression of B-cells, T-cells, natural killer (NK) 
cells, macrophages, mast cells, neutrophils  and dendritic cells (DCs) is mediated 
by diverse receptors, the intracellular signaling mechanisms are highly 
conserved. 
 
1.2.1  Stimulatory Immunoreceptors 
 
Most activatory receptors contain in their intracellular domains 
immunotyrosine-based activating motifs (ITAMs) or recruit co-receptors 
containing such motifs. These motifs share the consensus Tyr-X-X-(Leu/Ile)-
X(6-8)-Tyr-X-X-(Leu/Ile), where X can be any amino acid. ITAMs  were 
discovered in proteins involved in T-cell and B-cell receptor (TCR/BCR) 
signaling, in some Fc Receptors, and in the activating form of the killer 
immunoglobulin receptors (KIRs) (44). Upon stimulation of these receptors, for 
example by the binding of antigens to the TCR, the two tyrosines in the ITAM get 
phosphorylated by SFKs, which then enables the Syk-family kinases and ZAP-70 
to bind to these motifs with their tandem SH2 domains (45, 46).  Following their 
activation, the Syk-family kinases then phosphorylate adapters and downstream 
effectors such as the novel B-cell linker (Blnk), the linker molecule LAT and the 
SH2-domain containing linker protein SLP-76. The ensuing signaling cascade 
activating the cell has been well described, with the induction of PLCγ, protein 
kinase C (PKC), phosphoinositol-3-kinase (PI3K), the Ras/MAPK pathway and 
mobilization of intracellular calcium stores (47, 48). 
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1.2.2  Inhibitory Immunoreceptors 
 
Three major mechanisms are though to contribute to the negative regulation in 
the immune system. The inhibitory cytokines, as TGFβ and IL-10, inhibit 
inflammatory responses (49, 50), whereas facultatively inhibitory cytokines, as 
IL-4, can mediate inhibition or activation, depending on other stimuli (51). 
Apoptosis controls many steps in the development and responses of immune 
cells, as defects in the apoptotic pathways leads to lymphoproliferative and 
autoimmune diseases (52, 53). The third mechanism comprises the inhibitory 
immune receptors, which attenuate and downregulate activating signals. Knock-
out mice for these receptors produce autoantibodies, symptoms similar to 
systemic lupus erythematosus and arthritis similar to rheumatoid arthritis (54, 
55).  
The inhibitory receptors share three structural similarities: (i) an extracellular 
domain containing one or more immunoglobin- or lectin-like repeats, (ii) a 
transmembrane spanning region, and (iii) an intracellular domain containing 
between one to four immunotyrosine inhibitory motifs (ITIMs) or 
immunotyrosine-based switch motifs (ITSMs). The ITIMs were initially 
discovered in the FcγRII receptor and defined as (Ile/Val/Leu/Ser)-X-Tyr-X-X-
(Leu/Val) (56, 57). The ITSM was later identified in the intracellular domain of 
the CD150 receptor and defined as (Thr)-X-Tyr-X-X-(Leu/Val) (58-60). In most 
receptors, ITIMs/ITSMs are tandemly repeated, with a poorly conserved spacer 
sequence of about 15 to 30 amino acids between the motifs. Upon binding their 
extracellular ligands, such as MHC-I complex in the case of the inhibitory KIRs, 
the inhibitory immune receptors are tyrosine-phosphorylation by SFKs on these 
motifs. Intriguinly, the extracellular ligands of many inhibitory receptors have 
not yet been identified. Following their engagement, these receptors recruit 
phosphatases as the inositol phosphatase SHIP, SHP-1 and/or SHP2 to their 
ITIMs/ITSMs.  The ITSMs can additionally bind the adapter proteins SAP 
and/or EAT-2. 
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1.2.3  Inhibitory Signaling over ITIMs 
 
The tandem SH2-containing phosphatases SHP1 and SHP2 are predisposed to 
bind to the tandem ITIMs/ITSMs. Recruited to the inhibitory receptors they 
dephosphorylate tyrosine-phosphorylated proteins in the activatory cascades (61, 
62). While the effects of SHP1 recruitment by inhibitory receptors has been well 
documented (63), many  inhibitory receptors bind SHP1 and SHP2 
simultaneously, making it difficult to assess their individual contribution. This is 
further hampered by the embryonic lethality of SHP2 knock-outs. The ITIM-
containing CD31 receptor (PECAM-1) binds SHP1, SHP2 and was shown to 
negatively regulate the BCR/TCR signaling, as mice deficient in CD31 exhibit 
hyper responsive B-cells and developed autoimmune diseases (64).  While the 
inhibitory effect of CD31 was also present in normal B-cells which express both 
SHP1 and SHP2, the inhibition was abrogated in SHP2-deficient cells, indicating 
a requirement of SHP2 in the inhibitory signaling (65). In addidition, expression 
of a dominant-negative SHP2 but not a dominant negative SHP1 abolished the 
inhibition of cytotoxicity in NK cells by the KIR2DL5 receptor (66).  These data 
indicate that although both SHP1 and SHP2 can bind the same motifs and inhibit 
signaling, their functions are often not redundant. 
The initial report involving Csk in the inhibition of the immune signaling came 
from studying the effects of its overexpression in a T-cell line (67). In these cells, 
the TCR phosphorylation and the amount of secreted IL-2 were significantly 
reduced. In contrast, over-expressing Csk caused only minor effects on the 
phagocytic activity of macrophages, and no effects at all in B-cells (68, 69). 
Taking into account the knowledge that Csk associates to Cbp/PAG and inhibits 
SFKs activity, the following model was proposed for T-cells (62); Upon 
recognition of ligands by the TCR, Cbp/PAG undergoes dephosphorylation by an 
yet unknown mechanism and Csk leaves the membrane to become cytoplasmic. 
In doing so, Csk does not repress the SFKs anymore, which become activated and 
can initiate the activatory and inhibitory signaling by tyrosine-phosphorylating 
protein residues in the cluster of the TCR signaling complex.  With the PEST-
domain enriched protein tyrosine phosphatase (PEP) a protein binding the SH3 
domain of Csk was identified in an yeast two-hybrid screen (70). PEP is 
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exclusively expressed in hematopoietic cells, and predominantly (50-80%) 
constitutively associated to Csk. The association of Csk with PEP opened 
completely new views on the mechanisms by which it can act. The human 
homolog of the mouse PEP, the lymphoid phosphatase Lyp (PTPN22), can, 
associated to Csk, inhibit T-cell activation (71). Mutations in Lyp have been 
associated with a variety of autoimmune diseases as rheumatoid arthritis (72), 
systemic lupus erythematosus, Graves disease and susceptibility to type I 
diabetes (73). The risk variant associated to the susceptibility to type I diabetes 
encodes a mutation (R620W) in Lyp abrogating the binding of Csk to Lyp, 
stressing the importance of the association between Csk and tyrosine 
phosphatases in the regulation of the immune system. Through sequence 
homologies, a second binding partner to the SH3 domain of Csk was identified, 
the protein phosphatase PTP-PEST (74), which is ubiquitously expressed and 
associates in a wide range of cell types with Csk. While PTP-PEST has important 
roles in signaling in immune cells, it is also involved in controlling the assembly, 
migration, and cytokinesis of cellular focal adhesions (75) and preventing  the 
activation of the Ras pathway signaling (76).  
 
1.2.4  Inhibitory and Activatory Signaling over ITSMs 
 
While the concept of separate activatory and inhibitory receptors holds true in 
many cases, an additional layer of complexity is added by the presence of 
receptors containing ITSMs and having a dual function, switching the signaling 
to activation or inhibition depending on the availability of cytoplasmic adapter 
proteins.  
The SLAM (signaling lymphocitic activation molecules) subfamily of receptors 
encompasses six members (CD150, CD84, CD229, CD244, NTB-A, CS1), which 
contain no ITIMs but at least two ITSMs in their cytoplasmic domains. Other 
receptors integrate both motifs in their intracellular domain, such as PD-1, CD31, 
CD33, C-CAM (each containing one ITIM-ITSM tandem) and SHPS-1 (two ITIM-
ITSM tandems). The ITSM can, as mentioned earlier, bind to SHP1, SHP2, or 
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SHIP, and, additionally, to at least two adapter proteins, SH2D1A (SAP) and 
SH2D1B (EAT-2).  
SAP is a 15 kDa protein expressed in T- and NK cells (77), and contains only an 
SH2 domain and a short C-terminal tail. Mutations in the SH2D1A gene 
encoding SAP are associated to the X-linked immunoproliferative disease (XLP), 
characterized by impaired responses to viral infections and by the presence of B-
cell non-Hodgkin’s lymphoma (58). Surprisingly, SAP binds the ITSM in SLAM 
irrespectively of its tyrosine-phosphorylation, with an affinity comparable to the 
SH2-phosphotyrosine interactions (78), which is only increased about 5-fold by 
phosphorylating the tyrosine in the ITSM (79). The crystal structure for this 
small adapter protein revealed a novel mode of ligand binding. Whereas the 
classical SH2 domain recognizes its cognate peptide trough two surface pockets, 
the phosphotyrosine and the amino acids C-terminal to it, the unusual SH2 
domain of SAP uses three surface pockets, recognizing residues on both sides of 
the phosphotyrosine  (79). Both SHP2 and SAP bind to the same sites in SLAM, 
supporting the notion of a competition between both proteins. Indeed, it was 
shown that SAP, which has a higher affinity, blocks the binding of SHP2. In the 
absence of SAP, SHP2 binds with its tandem SH2 domains two ITSMs. If SAP is 
expressed, it displaces SHP2, occupies one ITSM, and the other ITSM becomes 
accessible to proteins like SHIP, which can also bind a single ITSM, although 
with a lower affinity than SHP2 (60, 78). Such a molecular switch changes the 
signaling capabilities of a receptor, depending on the cell type it is being 
expressed. Further studies revealed a recruitment of the Fyn kinase by SAP (80). 
This recruitment and therefore coupling of Fyn to the SLAM receptor is mediated 
by a small prominent non-proline based sequence in the SH2 domain of SAP, 
which binds the SH3 domain of Fyn, increasing its kinase activity markedly (81, 
82).  
EAT-2 is expressed in NK-, B-cells, macrophages, and DCs (77) and contains the 
same unusual SH2 domain as SAP, therefore binding to ITSMs. In contrast to 
SAP, it does not recruit kinases, but contains tyrosine-phoshorylation sites. NK 
cells from mice deficient for EAT-2 exhibit an increased killing rate and IFNγ 
secretion, supporting the idea of EAT-2 being a negative regulator of their SLAM 
receptor activity (83). EAT-2 is thought to recruit SHP1, SHP2 and/or Csk by 
means of its phosphotyrosines, exerting its inhibitory function by these effectors. 
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The function of EAT-2 in the context of the DCs is not known, and may give us 
novel understandings how our immune system coordinates its activities. 
The complex cell-type depending outcome of the signaling by a certain inhibitory 
receptor is exemplarily illustrated by SHPS-1 (MyD-1, BIT, SIRPα), which 
contains two ITIM-ITSM pairs.  When SHPS-1 is binding its ligand CD47 in 
macrophages, it inhibits their phagocytic activity (84) and at the same time 
induces their nitric oxide production (85), whereas the same binding in dendritic 
cells inhibits their maturation (80), and therefore effective antigen presentation. 
Co-ligation of this inhibitory receptor with FcεRI in mast cells inhibits their IgE-
induced production of cytokines (86). In monocytes, ligation of SHPS-1 inhibits 
the LPS-induced TNFα secretion (87).  
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1.3 Tyrosine-phosphorylated effectors of bacterial 
pathogens 
 
The immense importance of tyrosine-phosphorylation in eukaryotic signaling 
pathways opens the door for abuse by pathogens. By tweaking the signaling 
cascades with tyrosine-phosphorylated proteins or adapters, virtually any 
function of the host cell can be accessed and subverted. It is therefore not 
surprising that tyrosine-phosphorylation itself was first discovered being 
mediated by the protein of a pathogen (2). 
To subvert the eukaryotic signaling by means of tyrosine-phosphorylated 
effectors proteins, these proteins have in first place to be transported into these 
cells. Gram-negative bacteria have two membranes, the eukaryotic cells one. 
Bacteria have therefore elaborated complex machineries to secrete their effectors 
across these multiple membranes directly into the eukaryotic cell. Of interest 
here are the Type III secretion system (T3SS) and the Type IV secretion system 
(T4SS) of gram-negative bacteria. Both apparatuses are used for delivering 
effectors into host cells, where they are subsequently tyrosine-phosphorylated. 
The T3SS apparatus is a needle-like structure spanning both membranes of the 
bacterial cell, and secretes effector proteins as well as components of the 
apparatus. It shares many similarities with the flagellar hook basal body, 
suggesting an evolutionary relationship between both (88). 
The T4SS is, in contrast to the T3SS, evolutionarily related to conjugation 
machineries. It is capable of secreting proteins and additionally also DNA into 
host cells (89). 
 
The first bacterial effector protein reported to be tyrosine-phosphorylated was 
the translocated intimin receptor (Tir) of enteropathogenic Escherichia coli 
(EPEC) (90). At first mistakenly identified as a host-cell protein being tyrosine-
phosphorylated upon infection, this protein was shown to be secreted by the 
EPEC Type III T3SS. Upon secretion, Tir inserts into the eukaryotic membrane, 
where it acts as the receptor for the bacterial surface protein intimin, enabling 
intimate attachment of the bacteria to its host cell. Its intracellular domain gets 
tyrosine-phosphorylated on Y474 by SFKs (91) and binds the adapter protein Nck 
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(92). This adapter protein is composed of one SH2 and three SH3 domains and 
couples Tir to N-WASP, thereby inducing actin polymerization by the Arp2/3 
complex (93). This actin reorganization was shown to be crucial for the formation 
of pedestrals, which are membrane extrusions of the infected cells, on which the 
bacteria locate. 
The mouse pathogen Citrobacter rodentium also expresses a Tir protein, which 
was shown to be essential for virulence in a rodent model  to induce actin 
rearrangements and to be tyrosine-phosphorylated (94). Intriguingly, in contrast 
to the Tir of EPEC, it mediates the actin rearrangements independently of its 
tyrosine-phosphorylation. This finding stresses that - in addition to tyrosine-
phosphorylation dependent effects - the secreted effectors can also have a 
tyrosine-phosphorylation independent function. 
The obligate intracellular bacterium Chlamydia trachomatis is one of the most 
commonly sexually transmitted human pathogens and the etiologic agent of 
trachoma and lymphogranuloma venereum. This pathogen secretes the Tarp 
protein through its T3SS protein into human cells. In the case of HELA cells, 
Tarp was shown to be tyrosine-phosphorylated upon translocation and to recruit 
actin (95). While its exact function is not known, it has been hypothesized to play 
a role in the invasion of the host cells.  
The CagA protein of the human pathogen Helicobacter pylori is secreted by its 
T4SS upon attachment into gastric epithelial cells (96).  It has a size of 120-145 
kDa and contains in its C-terminus a variable number of “EPIYA” motifs, 
depending on the bacterial strain. These motifs were, based on their similarities, 
classified into EPIYA-A,-B,-C and -D. While CagA of Western H. pylori strains 
contain the motif combinations A-B-C, A-B-C-C, or A-B-C-C-C, the more virulent 
East-Asian counterparts express a CagA containing the A-B-D motifs (97, 98). 
EPIYA-C and -D are the most prominently tyrosine-phosphorylated motifs, 
whereas EPIYA-A and -B exhibit a reduced phosphorylation. Tyrosine-
phosphorylation of these motifs by host SFKs elicits what has been termed the 
“hummingbird phenotype” (99), which is characterized by increased host cell 
motility and elongation (100). While SHP2 and Csk have been reported to 
interact with CagA depending on its tyrosine-phosphorylation (101, 102), PLCγ, 
Grb2, c-Met do this independently of the phosphorylation state (103, 104). It has 
been proposed that Csk inhibits the phosphorylation of CagA by suppressing the 
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activity of the SFKs, therefore enabling an autoregulatory loop to control the 
amount of phosphorylated CagA (102, 105).  
A large number of studies suggest an increased risk for individuals, carrying 
CagA-positive H. pylori strains, to develop gastric cancer (106, 107). 
Concomitantly, studies reporting oncogenic proliferations associated to missense 
mutations in SHP2 showed the oncogenic potential of this phosphatase (36). 
SHP2 binds to the EPIYA-C and -D motifs in CagA. The severity of the gastric 
carcinoma or atrophic gastritis has been linked to the number of EPIYA-C motifs 
in Western H. pylori strains (98). In the more virulent East-Asian strains, the 
EPIYA-D motif was shown to have a stronger SHP2 binding and activation 
capacity than EPIYA-C (108). Even though the host genetic variability and 
susceptibility may play an important role in the severity of the disease by H. 
pylori, the CagA-SHP2 interaction is a prime candidate being responsible for the 
oncogenic transformations. 
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Bartonella and type IV secretion 
 
Bartonellae are gram-negative, facultative intracellular pathogens. They cause 
long lasting intra-erythrocytic bacteraemia in their mammalian species-specific 
reservoir hosts, facilitating the transmission by blood sucking arthropods. No 
intra-erythrocytic bacteraemia is detected in their incidental hosts, whereas they 
have in both the reservoir and the incidental hosts a tropism for endothelial cells. 
Currently, over twenty Bartonella species infecting a wide range of mammals are 
known, two having humans as reservoir host (B. bacilliformis and B. quintana), 
seven inducing diseases in humans as zoonotic pathogens, and fourteen not 
known to infect  humans as yet (109, 110). 
To elucidate the mechanisms of Bartonella infection, Schulein et al. developed an 
in vivo infection model for B. tribocorum, which has rats as reservoir hosts (111). 
Intravenously injected wild-type B. tribocorum are rapidly cleared from the 
bloodstream, which remains sterile for at least three days. The primary niche, 
which allows the bacterial to survive and replicate in these first three days is yet 
unknown. On day four, the bacteria re-appear in the bloodstream, adhere to and 
invade erythrocytes, where they replicate for a few rounds without shortening the 
lifespan of the erythrocyte. Approximately every five days, a new wave of bacteria 
enters the bloodstream and invades the erythrocytes, sustaining the bacteremia 
for about ten weeks. This is in accordance with other animal models (112). The 
affinity of Bartonella for endothelial cells in vitro and the fact that these cells 
coat the blood vessels suggests the endothelial cells being the primary niche, 
where the bacteria hide the first three to four days, and from where they seed into 
the bloodstream. 
B. henselae has cats as reservoir host, and is the etiological agent of cat scratch 
disease in incidentally infected immunocompetent humans. B. henselae has been 
furthermore associated with symptoms like endocarditis, bacteremia with fever, 
neuroretinitis, and, in immunocompromised individuals, with bacillary 
angiomatosis/peliosis (113). Bacillary angiomatosis is a Bartonella-triggered 
tumor-like vasoproliferation of endothelial cells, which in addition to B. henselae 
also B. quintana and B. bacilliformis can induce (114). Strikingly, B. henselae 
does also mediate anti-apoptosis in endothelial cells, a mechanism which might 
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support the induction of the bacillary angiomatosis (115). By infecting endothelial 
cells in vitro, it has been shown that B. henselae induced massive actin 
rearrangements in these cells, a structure which has been termed the  invasome 
(116).  
Bartonellae contain two T4SS which were shown to be essential for intra-
erythrocytic bacteremia in the animal model: the Trw and the VirB/VirD4 
systems (117, 118). The Trw system exhibits a high level of sequence identity to 
the conjugative machinery of the broad-host-range antibiotic-resistance plasmid 
R388 of E. coli. In contrast, the VirB/VirD4 system has its closests relative in the 
AvhB/TraG conjugation system of the cryptic plasmid pATC58 of Agrobacterium 
tumefaciencs, as we will show this in the first manuscript of this thesis. It is 
encoded by an operon of ten genes (virB2-virB11) and the virD4 gene closely 
located downstream. The VirB proteins form a pore complex encompassing both 
membranes of gram-negative bacteria and potentially the membrane of infected 
eukaryotic cells.  VirD4, also called the coupling protein, mediates the interaction 
between the VirB pore complex and the substrates being secreted by this 
apparatus, therefore coupling the secretion apparatus to the secreted proteins. In 
conjugative T4SS, the exported substrate is a DNA-protein complex, the protein 
being termed the relaxase. The relaxase cleaves and covalently attaches to one 
strand of the plasmid DNA, followed by the export of this protein-DNA complex 
by the plasmid encoded T4SS.  
 
The combined knowledge of Bartonellae using T4SSs to mediate pathogenicity,  
of other pathogenic bacteria secreting effectors by the means of such systems, 
and of the peculiar phenotypes B. henselae elicits in the endothelial cells, 
prompted us to look for VirB/VirD4 T4SS secreted effector proteins. Preliminary 
data indicated that the VirB T4SS of B. henselae mediates invasion, 
proinflammatory activation and antiapoptotic protection of endothelial cells 
(119), therefore associating phenotypes to the presence of an intact T4SS. The 
first manuscript in this thesis describes the discovery of seven putative 
substrates, the Bartonella exported proteins (Bep), being exported by the 
VirB/VirD4 secretion apparatus, the characterization of their modular 
organization and their secretion-mediating domain. The second manuscript 
focuses on BepE, where all data acquired so far indicate that this protein mimicks 
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inhibitory immune receptors. The third chapter in the results part contains the 
abstracts of two manuscripts, in which the effects of BepA and BepG on the 
endothelial cells are presented. Last, the fourth chapter contains unpublished, 
additional findings concerning BepD and BepF. 
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2. Aim of the Thesis 
 
Started in April 2002, the primary aim of this thesis was to investigate the 
VirB/VirD4 T4SS of Bartonella henselae for the presence of secreted substrates 
and signals mediating this secretion. Following the identification of these 
substrates, I then focused on the characterization of their functions and 
interaction partners in the host cell, with an emphasis on the putative tyrosine-
phosphorylated effectors. 
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Members of our group showed earlier that the T4SS of Bartonella tribocorum is 
essential to establish intraerythrocytic infection in an rat-infection model (1), and 
that the T4SS of B. henselae mediates subversion of endothelial cells upon 
bacterial infection (2). We report here the discovery and characterization of 
multiple protein substrates, subsequently termed Bartonella-translocated 
effector proteins (Beps), being translocated by the VirB/VirD4  T4SS of B. 
henselae into infected host cells. 
Sequencing 23 kb downstream of the virB locus of B. henselae, we found an open 
reading frame (ORF) encoding a coupling protein (virD4) and a group of seven 
ORFs encoding proteins with a common C-terminal domain, which was 
subsequently termed the Bartonella intracellular delivery (BID) domain. By 
constructing a Hidden Markov Model of these BID domains and querying protein 
databases, we found many similar domains in the relaxases of conjugative 
plasmids in the α-proteobacteria, as for example in the C-terminus of the TraA 
relaxase from the AvhB/TraG conjugation system in A. tumefaciens. We then 
showed that this BID domain of TraA was translocated trough the VirB/VirD4 
T4SS of Bartonella henselae. This finding does not only support the common 
evolutionary ancestry between the Bartonella T4SS and the T4SS of conjugative 
plasmids, but furthermore opened up the fascinating possibility that the 
Bartonella VirB/VirD4 T4SS is able to export DNA attached to a relaxase into 
host cells. No similarities were found between the BID domain and proteins 
being secreted in a T4SS-dependent manner by other pathogens (H. pylori, L. 
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pneumophila, A. tumefaciens) indicating a separate evolutionary ancestry. These 
data suggest that the VirB/VirD4/Bep system has rather recently evolved from 
the T4SS of conjugative plasmids.  
To demonstrate the translocation of the Beps through the VirB/VirD4 T4SS, we 
fused a FLAG-tag to the N-terminus of BepD and could show that BepD is 
translocated into infected endothelial cells in a VirB/VirD4 T4SS-dependent 
manner, whereupon it localizes to the cytoplasm of these cells and is tyrosine-
phosphorylated by host-cell kinases. The development of the Cre-recombinase 
reporter assay for translocation (CRAFT) made it possible to delineate precisely 
the translocation domain, which proved to be bipartite. In addition to the BID 
domain, a short, positively charged C-terminal amino acid sequence was needed 
for an effective delivery of proteins.  
To assess if the previously observed subversion of endothelial cells upon bacterial 
infection could be associated to the secretion of the Beps, we generated non-polar 
in-frame deletions of these seven putative T4SS effector proteins (ΔbepA-G) and 
a non-polar deletion of the ORF encoding the coupling protein (ΔvirD4). These 
mutants were abrogated in induction of all the described effects on the 
endothelial cells as (i) anti-apoptotic protection of endothelial cells, (ii) massive 
cytoskeletal rearrangements, termed the invasome (iii) cytostatic/cytotoxic 
effects at higher doses, and (iiii) activation of a pro-inflammatory response.  
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Statement of my own contribution 
 
I sequenced together with Ralf Schülein and Thomas Rhomberg the locus, 
coordinated and assembled the sequencing runs (Fig. 1). I described the BID 
domain (Fig. 1), constructed the Hidden Markov Model, and did the 
Bioinformatics for finding related domains (Fig. 4), which also led to the 
description of the translocation domain in the TraA relaxase of the AvhB/TraG 
system (Fig. 3). By the means of bioinformatics analysis and based on the 
modular structure of the Beps, I assisted in the planning of constructs used to 
delinate the secretion signal (Fig. 3). I also did the western blot in Fig. 3 for 
showing the stability of the Cre-BID fusion constructs. Finally, I constructed the 
FLAG-tagged BepD and did infection experiments to demonstrate protein 
translocation by two independent lines of evidence, tyrosine phosporylation and 
localization in the host cell cytoplasm (Fig. 2).  
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Bacterial type IV secretion (T4S) systems mediate the transfer of
macromolecular substrates into various target cells, e.g., the con-
jugative transfer of DNA into bacteria or the transfer of virulence
proteins into eukaryotic host cells. The T4S apparatus VirB of the
vascular tumor-inducing pathogen Bartonella henselae causes sub-
version of human endothelial cell (HEC) function. Here we report
the identification of multiple protein substrates of VirB, which,
upon translocation into HEC, mediate all known VirB-dependent
cellular changes. These Bartonella-translocated effector proteins
(Beps) A–G are encoded together with the VirB system and the T4S
coupling protein VirD4 on a Bartonella-specific pathogenicity is-
land. The Beps display a modular architecture, suggesting an
evolution by extensive domain duplication and reshuffling. The C
terminus of each Bep harbors at least one copy of the Bep-
intracellular delivery domain and a short positively charged tail
sequence. This biparte C terminus constitutes a transfer signal that
is sufficient to mediate VirBVirD4-dependent intracellular delivery
of reporter protein fusions. The Bep-intracellular delivery domain
is also present in conjugative relaxases of bacterial conjugation
systems. We exemplarily show that the C terminus of such a
conjugative relaxase mediates protein transfer through the Bar-
tonella henselae VirBVirD4 system into HEC. Conjugative relax-
ases may thus represent the evolutionary origin of the here
defined T4S signal for protein transfer into human cells.
conjugative relaxase  effector protein  endothelial cell  protein
translocation  antiapoptosis
Bacterial type IV secretion (T4S) systems are versatile trans-porters ancestrally related to bacterial conjugation ma-
chines. Present-day functions of T4S systems include (i) DNA
transfer into bacterial or plant cells by cell-to-cell contact, (ii)
protein delivery into mammalian or plant cells by cell-to-cell
contact, (iii) DNA release to or uptake from the extracellular
milieu, and (iv) release of multisubunit protein toxins to the
extracellular milieu (1, 2). The prototypic T4S system for in-
terkingdom substrate transfer is the VirB apparatus (encoded by
virB1–virB11) and associated T4S coupling protein VirD4 of the
phytopathogen Agrobacterium tumefaciens (At). This VirB
VirD4 T4S system mediates transfer of all components of the so
called T-DNA complex, which is composed of protein substrates
(VirD2 and VirE2) and single-stranded DNA (T-DNA), into
plant cells (3). Intracellular delivery of solely protein substrates
subverting host cell function (effector proteins) is considered to
represent the primary function of T4S systems in human patho-
genic bacteria (2). Examples include the Cag system of the gastric
pathogen Helicobacter pylori (Hp), which translocates the CagA
effector protein into gastric epithelial cells (4), and the DotIcm
system of the Legionnaires disease agent Legionella pneumophila
(Lp), which translocates multiple effector proteins into infected
macrophages (5, 6). Although reporter protein fusions with
subdomains of T4S substrates of At VirBVirD4 or Lp DotIcm
have indicated the requirement of C-terminal sequences for
interkingdom protein transfer (5, 7, 8), no conserved T4S signal
has been defined yet (1, 2).
Bartonella henselae (Bh) is a zoonotic pathogen causing a
broad range of clinical manifestations in humans, including
cat-scratch disease, bacillary angiomatosis-peliosis, bacteremia
with fever, and neuroretinitis. Bacillary angiomatosis-peliosis is
characterized by the formation of vasoproliferative tumors,
which result from bacterial colonization and activation of human
endothelial cell (HEC) (9). VirB, a T4S system closely related to
conjugative DNA-transfer systems of -proteobacterial plasmids
(10), is a major virulence determinant of Bh for subversion of
HEC function. VirB-dependent changes of HEC include (i)
massive cytoskeletal rearrangements resulting in cell-surface
aggregation and uptake of large bacterial aggregates by a defined
structure termed the invasome; (ii) induction of a proinflam-
matory phenotype by activation of NF-B, resulting in surface
expression of the cell adhesion molecules ICAM-1 and E-
selectin and secretion of the proinflammatory cytokine IL-8; (iii)
increased cell survival by inhibition of early and late events of
apoptosis (caspase activation and DNA fragmentation, respec-
tively); and (iv) cytostatic or even cytotoxic effects at high
infection doses, which interfers with a potent VirB-independent
mitogenic activity of Bh (11).
Here, we report the identification of the genes encoding the
T4S coupling protein VirD4 and seven putative effector proteins
[Bartonella-translocated effector proteins (Beps) A–G]. We pro-
vide evidence that VirD4 and at least one of the effector proteins
mediates all VirB-dependent phenotypes in HEC. Furthermore,
we exemplarily show BepD to be translocated into HEC in a
VirBVirD4-dependent manner. Based on sequence homology
between all seven Beps, we functionally define the signal for
VirBVirD4-dependent protein transfer and propose its evolu-
tionary origin from conjugative relaxases of bacterial conjuga-
tion systems.
Materials and Methods
Bacterial Strains, Cell Lines, and Growth Conditions. Bh and Esche-
richia coli strains were grown as described in ref. 11, and At C58
was grown on plates containing Luria–Bertani medium plus agar
at 28°C overnight. Table 1, which is published as supporting
information on the PNAS web site, lists all the strains used in this
This paper was submitted directly (Track II) to the PNAS office.
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study. Human umbilical vein endothelial cells (HUVEC) were
isolated and cultured as described in ref. 12. The endothelial cell
line Ea.hy926 resulting from a fusion of HUVEC and the lung
carcinoma cell line A549 were cultured as reported in ref. 13.
DNA Sequencing and Plasmid Construction. Sequencing of the bep
region of BhATCC 49882T was performed from a cosmid library
by using a primer walking strategy, starting with primers used for
the sequencing of virD4 ofBartonella tribocorum (10). Details are
described in Supporting Materials and Methods and Table 2,
which are published as supporting information on the PNAS web
site. The resulting sequence has been deposited in GenBank
under accession no. AJ556988. The nuclear localization signal
(NLS)–Cre–Bep fusion protein-expressing vectors (pRS49–
pRS124), the Cre-sensor vector (pRS56), and the BepD expres-
sion vector (pPG104) were constructed bymultiple cloning steps.
Sequences of oligonucleotides (Table 2), sources of gene cas-
settes, and further details of cloning steps are given in Supporting
Materials and Methods. Briefly, for the expression of NLS–Cre–
Bep fusion proteins in the bacteria, we first constructed pRS40,
which contains the coding sequence for an NLS–Cre fusion
protein under the control of the taclac promoter. Sequences of
interest of the bep genes were amplified from genomic DNA and
cloned into the region encoding the C terminus of the NLS–Cre
gene in pRS40, providing vectors for inducible expression of
NLS–Cre–Bep fusion proteins (pRS49–pRS124). pRS56 was
constructed for generation of cell line Ea.hy926pRS56-c#B1,
and it contains the successive arrangement of a loxH site, a
neomycin phosphotransferase (neo) gene followed by a termi-
nator, a loxP site, and an egfp gene encoding GFP. To express
FLAG-tagged BepD, we first constructed a vector containing
the coding sequence for the FLAG tag following the starting
methionine (MDYKDDDDK) under the control of the taclac
promoter (pPG100). bepD was amplified from genomic DNA
and cloned downstream of the FLAG tag in pPG100, which
yielded pPG104.
Construction of In-Frame Deletions and Complementation of the
Deletion Mutants. In-frame deletion mutants of Bh RSE247 were
generated by a two-step gene replacement procedure as de-
scribed in refs. 10 and 11. The virD4 mutant contains an
in-frame deletion of 1.63 kb in virD4. The bepB–G strain carries
a 14.33-kb chromosomal deletion resulting in a 51-bp cryptic
ORF composed of a 5 sequence of bepB and a 3 sequence of
bepG. To construct the bepA–G strain, a 1.49 kb in-frame
deletion in bepA was introduced into the bepB–G strain, which
resulted in a remaining 144-bp cryptic ORF composed of 5 and
3 sequences of bepA. Further details are provided in Supporting
Materials and Methods.
Fig. 1. The Beps mediate VirBVirD4-dependent invasion, antiapoptotic protection, proinflammatory activation, and control of proliferation of HEC. (A)
Structure of the virBvirD4bep locus encoding the VirB components (VirB2–VirB11), the T4S coupling protein (VirD4), and seven putative effector proteins
(BepA–G). (B) Domain structure of BepA–G. Yellow boxes represent tyrosine-containing sequence repeats resembling tyrosine-phosphorylation motifs (indicated
by Y). (C) VirB4VirD4Bep proteins are required for mediating characteristic actin rearrangements, which result in uptake of Bh aggregates by means of
invasomes. HUVEC infected with the indicatedBh strains were stained for F-actin. (Scale bar, 10m.) (D) VirB4VirD4Bep proteins are required for antiapoptosis.
Caspase-37 activity of HUVEC was measured after infection with the indicated Bh strains for 24 h, followed by induction of apoptosis by actinomycin D for the
indicated times. (E) VirBVirD4Bep proteins are required for NF-B-dependent proinflammatory activation. HUVEC were infected for the indicated time with
the indicatedBh strains, followed by quantification of IL-8 in the culture medium. (F) VirB4VirD4Bep proteins are required for controllingBh-stimulated HUVEC
proliferation. HUVEC infected with the indicated Bh strains were counted at the indicated time points, and proliferation indices were calculated. (D–F) Triplicate
samples  standard deviation.
Schulein et al. PNAS  January 18, 2005  vol. 102  no. 3  857
M
IC
RO
BI
O
LO
G
Y
37
Caspase Activity, IL-8 Secretion, and Proliferation. The infection of
HEC and the determination of caspase-3 and caspase-7 activity
[multiplicity of infection (moi)  100], secretion of IL-8 (moi 
300), and cell proliferation (moi  30) were carried out as
described in ref. 11.
Immunocytochemical Stainings and Immunoprecipitation.HECwere
infected with Bh strains, stained for F-actin, total bacteria, and
extracellular bacteria or anti-FLAG M2. To assess the tyrosine
phosphorylation of BepD upon translocation by the T4S system,
Ea.hy926 cells were infected with Bh strains expressing FLAG-
tagged BepD. Cells were subsequently lysed, and the FLAG-
tagged BepD was immunoprecipitated with anti-FLAG agarose
and probed with antiphosphotyrosine antibody in a Western
blot. Experimental details are described in Supporting Materials
and Methods.
Cre Recombinase Reporter Assay for Translocation (CRAFT). CRAFT
(7, 8) was used to monitor the translocation of NLS–Cre–Bep
fusion proteins from Bh into Ea.hy926 cells stably transfected
with pRS56 (clone Ea.hy926pRS56-c#B1). After transport to
the nucleus, the fusion protein recombines two lox sites in
pRS56, thereby excising neo and the terminator, which resulted
in expression of eGFP. Briefly, Ea.hy926pRS56-c#B1 were
infected with Bh strains harboring plasmids containing NLS–
Cre–Bep fusions, trypsinized after 120 h, and analyzed by flow
cytometry. To monitor the stability of NLS–Cre–Bep fusions in
Bh, steady-state protein levels in total lysates of bacteria grown
on isopropyl -D-thiogalactoside-containing medium were de-
termined by immunoblotting with anti-Cre antibodies. Experi-
mental details are described in Supporting Materials and Methods.
Bioinformatic Analysis. The putative C-terminal transfer domains
of Bh BepA–G were aligned by CLUSTALW. The alignment was
further edited manually, and a hidden Markov model was built
thereof. By using this model, we queried the UniProt database
(14) as described in SupportingMaterials andMethods. Sequences
of interest were aligned, and a neighbor-joining tree was gen-
erated as described in Supporting Materials and Methods.
Results
Bh Carries a Pathogenicity Island (PAI) Encoding the VirBVirD4 T4S
System and Seven Putative Protein Substrates.Assuming functional
clustering of the operon encoding the previously described VirB
apparatus (virB2–virB11) (15) with genes encoding further T4S-
related functions, we sequenced 23,294 base pairs that were
downstream of virB11 (Fig. 1A) (GenBank accession no.
AJ556988). Among the 10 genes encoded by this region, only the
distal mviN and trpS are present in the chromosome of related
-proteobacteria, suggesting that these genes belong to the
ancestral core genome (16). A cryptic prophage integrase gene
upstream of mviN indicates that the flanking region may have
been acquired by horizontal gene transfer (16). Based on criteria
defined by Hacker et al. (17), the virB operon and the eight
downstream-located genes may constitute a PAI. The second
gene downstream of virB11 encodes the T4S coupling protein
VirD4. The remaining seven genes of the PAI code for putative
VirBVirD4-translocated effector proteins, which we termed
BepA–G. Sequence analysis revealed a modular domain struc-
ture for BepA–G (Fig. 1B). BepA–C are homologues carrying an
N-terminal filamentation induced by cAMP (Fic) domain, which
is implicated in bacterial cell division (18) and is conserved in
many bacterial species (Fig. 1B and Fig. 5, which is published as
supporting information on the PNAS web site). The N-terminal
regions of BepD–F contain repeated tyrosine-containing pep-
tide sequences that resemble tyrosine-phosphorylation motifs
(e.g., EPLYA, Fig. 1B and Fig. 6, which is published as support-
ing information on the PNAS web site). Strikingly, all Beps share
at least one copy of a domain of 140 aa in their C-terminal
region (Fig. 1B and Fig. 7, which is published as supporting
information on the PNAS web site). This domain was suspected
to be involved in Bep translocation and was thus designated the
Bep intracellular delivery (BID) domain. In addition to the BID
domain, the C termini of BepA–G contain short unconserved
tail sequences rich in positively charged residues, each carrying
a net positive charge (Table 3, which is published as supporting
information on the PNAS web site).
All Known VirB-Dependent Cellular Phenotypes of HEC Require VirD4
and at Least One of the Putative Effector Proteins BepA–G. To test
whether VirD4 and BepA–G contribute to VirB-mediated
virulence, we generated nonpolar in-frame deletion mutants
(virD4 and bepA–G, the latter mutant being constructed by
sequential deletion of bepB–G and bepA) and compared them
with the isogenic virB4 mutant and wild-type strain with
respect to known VirB-dependent phenotypes of Bh-infected
HEC (11). Opposed to wild type, all three deletion mutants
were deficient for triggering (i) the formation of the charac-
teristic F-actin rearrangements associated with invasome-
mediated invasion (Fig. 1C and Table 4, which is published as
supporting information on the PNAS web site), (ii) the inhi-
bition of apoptotic cell death triggered by actinomycin D as
measured by caspase-37 activity (Fig. 1D), (iii) the activation
of an NF-B-dependent proinf lammatory response deter-
mined by quantification of secreted IL-8 in the culture medium
(Fig. 1E), and (iv) cytostaticcytotoxic effects interfering with
the VirB-independent mitogenic activity of Bh as measured by
cell counting (Fig. 1F). We conclude that all known VirB-
mediated phenotypes of HEC require the T4S coupling protein
Fig. 2. BepD becomes tyrosine-phosphorylated after VirB4-dependent
translocation into HEC. (A) VirB4-dependent translocation of BepD into HEC
results in tyrosine phosphorylation and a coincident reduction in electro-
phoretic mobility. Total protein extracts of Ea.hy926 cells uninfected (lane 1)
or infected with virB4 (lane 2), wild type (lane 3), virB4pPG104 (lane 5), or
wild typepPG104 were prepared. FLAG-BepD encoded by pPG104 was im-
munoprecipitated with anti-FLAG antibodies, separated by SDSPAGE, and
immunoblotted with anti-FLAG (Left) or anti-phosphotyrosine antibodies
(Right). (B and C) Immunocytochemical detection of FLAG-BepD after VirB
VirD4-mediated translocation into HEC. Ea.hy926 cells were infected with
wild-type (B) or the virB4 mutant (C), each harboring pPG104. Specimens
were immunocytochemically stained for the FLAG epitope (green), F-actin
(red), and bacteria (blue). (Scale bar, 10 m.)
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VirD4 and at least one of the putative effector proteins
BepA–G. Moreover, these data suggest that most likely all
genes encoded by the virBvirD4bep PAI of Bh have functions
related to T4S.
BepD Is Translocated into HEC in a VirB-Dependent Manner.Next, we
tested whether BepD, one of the three putative substrates for
host cell tyrosine kinases among the Beps (Fig. 1B), becomes
tyrosine-phosphorylated during infection of HEC. Phosphory-
lation by host cell tyrosine kinases was previously used to
demonstrate translocation of bacterial proteins into human cells
(19). We show that FLAG-epitope-tagged BepD becomes ty-
rosine-phosphorylated during HEC infection when expressed in
wild type but not in the virB4 mutant (Fig. 2A Right). Tyrosine
phosphorylation coincided with a prominent shift in electro-
phoretic mobility (Fig. 2A Left), suggesting additional protein
modification. Immunocytochemistry revealed a VirB4-
dependent punctuate staining pattern of FLAG-BepD in the
host cell cytoplasm (Fig. 2 B and C). Together, these data
demonstrate VirB-dependent translocation of BepD into HEC.
Fig. 3. The C-terminal translocation signal of Beps mediates VirBVirD4-dependent protein transfer into HEC. Protein transfer was determined by CRAFT. The
Cre-tester cell line Ea.hy926pRS56-c#B1 was infected with the indicated Bh strains expressing different NLS–Cre fusion proteins (plasmid names are indicated
in blue inA–E or black in F). The region of a given Bep fused to the C terminus of NLS–Cre is specified by the respective first and last amino acids (except for pRS96,
which expresses only NLS–Cre). Percentages of GFP-positive cells as determined by FACS analysis are indicated in red. (A) NLS–Cre fused to the C-terminal 183
aa of BepD translocates efficiently into HEC in a VirBVirD4-dependent manner. Dot blots of forward scatter (FSC) and GFP fluorescence (FL-1) are shown for
the indicated Bh strains. (B) Relative translocation efficiency mediated by the BID domain of BepB, BepC, and BepF. (C) The signal for VirBVirD4-dependent
translocation into HEC is bipartite, composed of the BID domain and an adjacent unconserved C-terminal tail. (D) Creation of an efficient bipartite translocation
signal by fusing a BID domain of BepF and the C-terminal tail of BepD. (E) The C terminus of the relaxase TraA of At plasmid pATC58 contains a BID domain and
mediates efficient protein transfer from Bh into HEC. (F) Steady-state NLS–Cre fusion protein levels in Bh grown on isopropyl -D-thiogalactoside-containing
medium.
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Delineation of the Bipartite T4S Signal of the Beps. To delimit the
BepD translocation signal and to demonstrate translocation of
other Beps, we adapted CRAFT, a reporter assay originally
designed to detect translocation of bacterial effector proteins
into plant cells (8) (Fig. 3A and Fig. 8, which is published as
supporting information on the PNAS web site). After infection
of the Cre-tester cell line Eahy.926pRS56-c#B1 with Bh strains
expressing NLS–Cre–recombinase fusion proteins, the percent-
age of GFP-positive cells (gpc) as determined by FACS analysis
was used as a relative measure for the efficiency of protein
transfer from Bh into HEC. Expression of an NLS–Cre–
recombinase fusion protein in wild-type Bh resulted in 0.0% gpc
and was thus negative in this assay (Fig. 3A, pRS96). In contrast,
NLS–Cre fused to the C-terminal 183 aa of BepD (BID domain
plus a short positively charged tail sequence, pRS51) was effi-
ciently translocated from wild-type (11.8% gpc) and bepA–G
(3.0% gpc), whereas no translocation occurred from virB4 or
virD4 strains (0.0% gpc) (Fig. 3 A and F). Hence, this heter-
ologous fusion protein was translocated in a VirB4VirD4-
dependent, and essentially Bep-independent, manner. Similar as
for BepD, NLS–Cre fusions to the BID domain-containing C
terminus of BepB, BepC, and BepF were translocated into HEC,
albeit at lower frequency (Fig. 3 B and F). Taken together, we
provide evidence for a functional T4S signal in the C terminus
of four Bep proteins (BepB, BepC, BepD, and BepF).
To further delimit the T4S signal contained in the 183-aa
C-terminal fragment of BepD, we performed a deletion analysis
(Fig. 3C and F). C-terminal deletion of 20 aa of the short positively
charged C-terminal tail sequence almost completely abolished
translocation (0.1% gpc). Stepwise deletion of the BID domain
from theN terminus resulted in a gradual reduction of translocation
efficiency. Together, these data suggest a bipartite translocation
signal at the C terminus, composed of a BID domain and a short
positively charged tail sequence. As illustrated in Fig. 3D, this
notion was supported by the success in creating an efficient trans-
location signal (1.9% gpc) via fusion of a translocation-inefficient
BID domain of BepF (0.1% gpc) with the translocation-deficient
positively charged tail of BepD (0.0% gpc). Notably, all NLS–Cre–
Bep fusion proteins analyzed by CRAFT displayed comparable
steady-state protein levels in bacteria (Fig. 3F), indicating that the
low translocation efficiency observed for several fusion proteins
does not result from protein instability but rather reflects the
absence of an appropriate T4S signal.
Identification of BID Domains in Conjugative Relaxases and Demon-
stration of Their Function As T4S Signal for the Bh VirBVirD4 System.
To search for other proteins containing a BID domain, we
queried the UniProt database with a hidden Markov model (20)
generated from an alignment of all BID domains of BepA–G
(Fig. 7 and Table 5, which is published as supporting information
on the PNAS web site). Among the 40 top hits are 27 hits within
putative T4S substrates. These hits include BepA–G of Bh and
their homologues in Bartonella quintana, annotated as hypothet-
ical proteins in the recently published genome sequences (16), as
well as Fic-1, which is a BepA homologue in Bartonella triboco-
rum (10). The other hits in putative T4S substrates are all in
relaxases of conjugative plasmids found in various -proteobac-
teria. The plasmid-borne conjugation systems associated with
these conjugative relaxases are closely related to each other as
well as to the Bh VirBVirD4 system (10), as indicated by
clustering in one clade of a phylogenetic tree for VirD4TraG-
like T4S coupling proteins (Fig. 4, cluster A). Interestingly, no
BID domain was found in protein substrates of agrobacterial
T-DNA transfer systems (VirBVirD4), which cluster in a
separate clade of the VirD4TraG phylogram (Fig. 4, cluster B),
or in the T4S substrates of Lp or Hp. For the AvhBTraG
conjugation system of At plasmid pAtC58 (21), we show that the
C terminus of its relaxase harbors a BID domain and a positively
charged tail sequence, which efficiently directs VirBVirD4-
dependent protein transfer from Bh into HEC (Fig. 3E,
pRS114), whereas the positively charged tail alone did not result
in detectable transfer activity (Fig. 3E, pRS115). These data
suggest that the Bh VirBVirD4Bep protein transfer system
evolved rather recently from one of the wide-spread conjugative
plasmid-transfer systems in -proteobacteria and that the bipar-
tite transfer signals in the substrates of these T4S systems are
functionally interchangeable.
Discussion
In this study, we characterized a PAI encoding presumably all
proteins related to the function of a pathogenesis-related T4S
system in Bh. In addition to the previously described T4S
apparatus VirB (VirB2–VirB11) (11, 15), this PAI encodes the
T4S coupling protein, VirD4, and seven T4S substrates termed
BepA–G. Deletion of either virD4 or the complete set of bep
genes (bepA–G) resulted in a similar phenotype as that described
for deletion of virB4 (11); i.e., these mutants are deficient for
subverting multiple HEC functions related to the cytoskeleton
and to inflammation, apoptosis, and proliferation. The essential
role of VirD4 for mediating VirB-dependent host cellular
changes is consistent with the proposed function as T4S coupling
protein, representing the interface between the T4S apparatus
and the translocated substrates (1). The loss of all known
VirBVirD4-dependent HEC changes in the bepA–G mutant
indicates that BepA–G may comprise the complete set of
VirBVirD4-translocated effector proteins. Preliminary data
Fig. 4. The coupling proteins (VirD4TraG) of T4S systems containing a BID
domain in their protein substrate(s) form a distinct phylogenetic cluster. This
cluster is formed by Bartonella VirBVirD4 systems and -proteobacterial
conjugative DNA transfer systems (cluster A) and does not contain agrobac-
terial T-DNA transfer systems (cluster B). VirD4TraG protein sequences were
extracted from the Uniprot database and then aligned and diagrammed as an
unrooted neighbor-joining radial tree. T4S systems containing a BID domain
in one of their substrate(s) are marked in bold (compare with Table 5). The
following sequences (with corresponding accession numbers) are included.
At: plasmid pAT (Q8UKJ4), pTiC58 (Q44346 and P18594), pTiA6NC (Q44360
and P09817), pRi1724 (Q9F5E3 and Q9F585), pTi15955 (Q8VLK3), and
pTiAB273 (Q8VT85); Agrobacterium rhizogenes: pRiA4b (Q93UY7 and
P13464); Bh (Q6G2A8); Bartonella quintana (Q6FYV9); Bartonella tribocorum
(Q8GJ55); Escherichia coli: pKM101 (Q46706) and R388 (Q04230); Hp
(Q75XB9); Lp (Q9RLR2); Oligotropha carboxydovorans (Q6LB53); Rhizobium
etli: p42d (Q8KL68);Rhizobiummeliloti: pSymA (Q92ZI3); andRhizobium spp.:
pNGR234a (P55421).
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from our laboratory suggest that the specific contribution of
individual Beps to the complex VirBVirD4-dependent pheno-
typic changes of HEC can be assessed by their expression, either
alone or in combination, in the effector-free bepA–G mutant
background (M.C.S., P.G., and C.D., unpublished data).
The recently published comparative genome analysis of Bh
and Bartonella quintana revealed that the virBvirD4bep PAI
characterized herein is present in both Bartonella genomes but
not in any other published genome sequence. However, in
contrast to the highly conserved virBvirD4 loci, the bep loci
display a high degree of plasticity, including signatures of gene
duplication and degradation (data not shown) as well as intra-
genic domain duplication and intragenic or intergenic domain
reshuffling (Fig. 1B). As a result, the domain structure of the
Beps is highly modular. The N termini of BepA–C are composed
of a domain (Fic) conserved in many bacterial species that is
considered to be involved in cell division (18). The N termini of
BepD–F contain short repeated peptide sequences containing
conserved putative tyrosine phosphorylation motifs (i.e.,
EPLYA) similar to the EPIYA motif of the CagA effector
protein of Hp known to be phosphorlyated by human Src-family
kinases (4, 22). Consistently, we show BepD to become tyrosine-
phosphorylated upon T4S-dependent transfer into HEC. Taken
together, the N termini of the Beps are highly divergent and may
primarily serve effector functions within HEC. In the C-terminal
region of all Beps, we could define at least one copy of a 142-aa
domain called BID. An unconserved, positively charged tail
sequence at the C terminus and the proximal BID domain was
shown here to represent a bipartite T4S signal that mediates
VirBVirD4-dependent protein transfer into HEC. This finding
is in agreement with a requirement of C-terminal sequences for
interkingdom transfer of T4S substrates of At and Lp (5, 7, 8).
A hidden Markov model of the BID domain alignment from
Bh allowed us to search for other proteins containing a similar
domain. A large proportion of the top hits were indeed within
putative T4S substrates, including all Bep homologues of bar-
tonellae as well as the conjugative relaxases of plasmid-borne
bacterial conjugation systems present in various -proteobacte-
ria. Conjugative relaxases direct the transfer of plasmid DNA by
first cleaving and covalently attaching to one DNA strand,
followed by transport of the resulting protein–DNA conjugate by
the plasmid-encoded T4S system (23). In this process, the
specific interaction between the relaxase and the T4S coupling
protein is thought to initiate the transport through the mem-
brane-spanning T4S channel (24). The BID domain has likely
evolved in the relaxases of -proteobacterial conjugation systems
before horizontal transfer occurred into a progenitor of Bar-
tonella. A phylogenetic analysis of the T4S coupling proteins
(VirD4TraG) of representative T4S systems indeed revealed
that the coupling proteins of T4S systems with a BID domain in
their substrate(s) form a distinct cluster. This finding suggests
coevolution of the coupling protein and the T4S signal, which is
consistent with the finding that coupling proteins and T4S
substrates physically interact (24–26). The absence of a BID
domain in the substrates of other T4S systems (e.g., of the
agrobacterial VirBVirD4 system, the Hp Cag system, and the
Lp DotIcm system) suggests that a different signal mediates
protein transfer by these T4S systems.
We show that the BID domain and short positively charged
C-terminal tail of the conjugative relaxase (TraA) of the At
pAtC58 conjugation system AvhBTraG is functional for medi-
ating VirBVirD4-dependent protein transfer from Bh into
HEC. The T4S signals of these related T4S systems involved
either in interbacterial DNA transfer or interkingdom protein
transfer are thus interchangeable. This finding makes it tempting
to speculate that conjugative relaxases are also transported by
the Bh VirBVirD4 system into HEC when they are covalently
attached to their single-stranded DNA substrate, similar to the
interkingdom DNA transfer by the At VirBVirD4 system into
plant cells. T4S-mediated DNA transfer from virulence-
attenuated Bh in human cells could have important applications
for gene therapy and vaccination and should thus be an inter-
esting subject for future investigations.
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Molecular mimicry of inhibitory immune receptors 
by the bacterial pathogen Bartonella 
 
Patrick Guye, Hermine Schein, Thomas Rhomberg,  Paul Jenö, and Christoph 
Dehio 
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The BepE protein of B. henselae contains putative tyrosine-phosphorylation sites 
in its N-terminus, and two C-terminal BID domains thought to mediate the 
translocation of this protein from the bacteria into the host cells in a  
T4SS-dependant manner (1). 
Here we show that upon translocation, BepE is tyrosine-phosphorylated in its N-
terminus, acquires a membrane-proximal localization, and additionally co-
localizes with VE-Cadherin at cell-cell contacts in human umbilical endothelial 
vein cells (HUVECs). Purified BepE is tyrosine-phosphorylated in vitro by the c-
Src kinase. We describe five putative tyrosine-phosphorylation sites in the N-
terminus of this protein, the first similar to a known binding site for the C-
terminal c-Src kinase (Csk) in VE-Cadherin, followed by two tandems of 
immunotyrosine inhibitory and immunotyrosine-based switch motifs (ITIMs, 
ITSMs). These motifs are widely present in the intracellular domain of inhibitory 
immune receptors of mammals. By recruiting SHP1, SHP2, SHIP and Csk to 
these motifs, the inhibitory receptors do inhibit the activation in almost all cells 
of the immune system. By means of co-immunoprecipitation, we show that both 
Csk and SHP2 bind BepE in a tyrosine-phosphorylation dependent manner. 
Performing a systematic exchange of tyrosines to phenylalanines in the N-
terminus of BepE, we showed that Csk binds only to the first motif. In contrast, 
to abrogate all binding of SHP2 to BepE it was necessary to mutate both ITIM-
ITSM tandems. The data accumulated so far highly suggest that BepE mimicks 
inhibitory immune receptors. To show this, we initiated a collaboration with 
Prof. Gennaro de Libero. This collaboration is ongoing, but due to the time 
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constraints of my Ph.D. thesis, cannot come to conclusion in this preliminary 
manuscript.   
 
 
Statement of own contribution 
 
I did the initial purification of HIS-tagged BepE, and initial in vitro and in vivo 
phosphorylation assays, leading to the detection of two phosphorylation sites in 
vitro and one in vivo. Hermine Schein further optimized the purification of HIS-
tagged BepE, and continued the mapping in collaboration with Paul Jenö’s lab 
(mass spectrometry analysis), which is still ongoing. The plasmid pTR1173 was  
constructed by Thomas Rhomberg. Matthias Selbach from the laboratory of 
Matthias Mann investigated the first tyrosine-phosphorylated motif of BepE in 
the SILAC screen, confirming Csk as an interaction partner for this motif. All 
other data/constructs reported in this manuscript were generated by me. 
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Abstract 
 
Inhibitory receptors suppress activatory signals in a wide variety of immune cells 
by binding and activating phosphatases and kinases, such as SHP2 and the 
C-terminal c-Src kinase (Csk). Here we show that the VirB/VirD4 Type IV 
secretion system (T4SS) of the vascular tumor-inducing pathogen Bartonella 
henselae (Bh) to secrete a protein, termed BepE, into infected cells, where it 
localizes to the cell plasma membrane and to cell-cell contacts. Upon secretion, 
this protein is tyrosine-phosphorylated by host-cell kinases on its 
immunotyrosine inhibitory motifs (ITIM), immunotyrosine switching motifs 
(ITSM) and a Csk binding-like motif located in its N-terminus, and binds 
subsequently Csk and SHP2. We show for the first time a molecular mimicry of 
such an inhibitory receptor being used by a pathogen to subvert the host cell 
signaling. 
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Introduction 
 
Bartonellae are gram-negative, facultative intracellular pathogens, capable of 
inducing vasoproliferative tumors known as bacillary angiomatosis  (1).  They can 
cause long-lasting intra-erythrocytic bacteremia in their mammalian reservoir 
hosts (2) and subvert multiple endothelial cells functions such as proliferation, 
apoptosis, inflammation, and cytoskeletal rearrangements (3, 4). Recently, we 
showed that Bartonella henselae (Bh) secretes seven proteins, termed BepA-G, 
into infected host cells through the VirB type IV secretion system (T4SS) (4). The 
BID domain of these proteins, which is located at their C-termini, mediates their 
secretion, whereas the N-termini encode putative effector functions. Three of 
these secreted proteins, BepD-F, contain putative tyrosine-phosphorylation 
motifs in their N-termini. We showed exemplarily for BepD that this protein is 
tyrosine-phosphorylated upon secretion into host cells (4). 
Tyrosine-phosphorylation plays a key role in many signaling cascades of 
eukaryotic cells. It is therefore not surprising that multiple bacterial pathogens 
evolved tyrosine-phosphorylated effector proteins to interfere with and subvert 
the functions of the host cells they infect (5).  Most prominent examples are the 
TIR and Tarp proteins secreted by the Type III secretion system of 
enteropathogenic Escherichia coli (6) and Chlamydia trachomatis (7), 
respectively, and CagA, which is secreted by the T4SS of Helicobacter pylori into 
gastric epithelial cells (8). All three effectors are tyrosine-phosphorylated upon 
translocation into the host cells by host cell kinases (5) and elicit effects as 
various as enhanced bacterial adherence, invasion, or hypermotility of the host 
cells.  
The immune system of mammals faces a tough dilemma. It has evolved to be 
exquisitely sensitive in detecting foreign antigens and abnormal or malignant 
cells, yet, it must synchronously tolerate a huge variety of stimuli associated with 
the normal processes and cells present in the organism. In this delicate balance, 
inhibition of the many immune system components is as important as their 
activation. One of the key components mediating the inhibition are the inhibitory 
immune receptors (9). Almost all cells of the immune system express at least one 
type of these receptors, most cells many, as in the example of the B cells where 
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there are at least fourteen distinct inhibitory receptors known to be expressed 
simultaneously (10).  Distinctive features of these receptors are an extracellular 
part containing one or more immunoglobulin- or lectin-like domain, a 
hydrophobic transmembrane region, and between one to four immunotyrosine 
inhibitory motifs (ITIMs) on the intracellular side (11). The consensus for these 
ITIMs has been defined as (Ile/Val/Leu/Ser)-X-Tyr-X-X-(Leu/Val), where X 
denotes any amino acid, and was initially discovered in the FcγRII receptor (12, 
13). These motifs can, upon tyrosine-phosphorylation by Src Family Kinases 
(SFK), bind to the SH2 domains of non-receptor phosphatases such as SHIP, 
SHP1, SHP2, and in some cases Csk (14). Bound to SHP1/SHP2 or Csk, the 
receptors can subsequently dephosphorylate immunotyrosine activation motifs 
(ITAMs) containing receptors or their tyrosine-phosphorylated substrates, which 
are for example present in the B-cell or T-cell receptors  (BCR / TCR) signaling 
clusters, or elicit directly signaling events in these cells (10, 15).  A derivative of 
the ITIM is the immmunotyrosine switching motif (ITSM) with the consensus 
(Thr)-X-Tyr-X-X-(Leu/Val). This motif is present in the CD150 subfamily of 
immune receptors (16) and can additionally bind adaptors such as SAP or EAT-2 
to signal, depending on the cell type, in a inhibitory or activatory way (17). 
Knowing the effects of these inhibitory receptors, it comes as no surprise that 
deletions in loci containing these receptors have been associated with 
autoimmune diseases. Knock-out mice for almost all inhibitory receptors exhibit 
symptoms of autoimmune diseases, as producing autoantibodies, or symptoms 
similar to systemic lupus erythematosus and arthritis resembling rheumatoid 
arthritis (18). 
Here we characterize the BepE protein of B. henselae, which is secreted into 
infected host cells in a T4S system-dependent manner and which contains two 
ITIM-ITSM tandems, additionally a motif for binding to the SH2 domain of Csk. 
We show that upon secretion into the host cells BepE becomes tyrosine-
phosphorylated in these motifs by SFKs and subsequently associates with Csk 
and the tyrosine phosphatase SHP2. Moreover, BepE was found to localize to the 
plasma membrane and in particular to cell-cell contacts in a phosphorylation-
independent manner. Together these data suggest for the bacterial BepE protein 
molecular mimicry of immunotyrosine inhibitory motifs-containing receptors, to 
our knowledge the first example of such mimicry by a pathogen.  
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Results 
 
BepE is tyrosine-phosphorylated upon translocation into the host 
cell.  Bh does exhibit a remarkable tropism towards primary human endothelial 
cells (HUVECs), where it induces a wide range of effects (3). To assess the 
tyrosine-phosphorylation of BepE upon translocation into HUVECs by the T4SS, 
we infected these cells with Bh strains expressing a FLAG-tagged BepE. 
Subsequently, we lysed the cells, immunoprecipitated the FLAG-tagged BepE 
with anti-FLAG agarose and probed the precipitate by western blotting with an 
anti-phosphotyrosine or an anti-FLAG antibody. BepE was tyrosine-
phosphorylated upon translocation into HUVECs as shown in Fig. 1, whereas in a 
secretion-defective mutant BepE was retained in the bacteria and therefore not 
accessible to the host cell kinases.  
 
 
The two C-terminal BID domains of BepE are sufficient for 
membrane localization and for co-localization with VE-Cadherin in 
infected HUVECs. HUVECs and HELA cells were infected with Bh strains 
expressing MYC-tagged BepE (aa 1-464) or the MYC-tagged C-terminal part of 
BepE encompassing the two BID domains (aa 136-464) (Fig. 2a). Using 
immunofluorescence labeling, the proteins could be detected in association with 
the plasma membrane of HELA cells (Fig. 2b). The weaker signal in the case of 
the MYC-tagged C-terminal part of BepE might be due to a folding not optimally 
exposing the MYC-tag or to reduced stability of the N-terminally truncated 
protein. Furthermore, both tagged proteins localize to the cell-cell contacts of 
HUVECs (Fig. 2c) as shown by the overlapping staining for the MYC-tag and the 
endothelial adherence junction marker VE-Cadherin. 
 
BepE is tyrosine-phosphorylated in vitro by the c-Src kinase. It has 
been shown that c-Src acts as the kinase of other tyrosine-phosphorylated 
bacterial effectors (19, 20). To test whether c-Src also mediates phosphorylation 
of BepE we expressed and purified HIS-tagged BepE and incubated it together 
with c-Src and ATP in vitro. BepE became tyrosine-phosphorylated as shown in 
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Fig. 3. In contrast, without c-Src, there was no detectable tyrosine-
phosphorylation, excluding the possibility of BepE autosphosphorylation. 
Noticeably, tyrosine-phosphorylated BepE exhibited a slightly increased 
apparent mass in the SDS/PAGE gels. 
 
 
Mapping the phosphorylated tyrosines of BepE by mass spectrometry. 
In vitro phosphorylated and unphosphorylated HIS-BepE was digested by 
proteases as described in Materials and Methods and subjected to mass 
spectrometry analysis. FLAG-tag containing BepE, co-expressed in HEK293T 
cells with or without the c-Src kinase was immunoprecipitated and analyzed 
likewise.  Table 1 shows the peptide fragments detected in the in vitro tyrosine-
phosphorylation mapping screen. Four out of the five putative tyrosine 
phosphorylation motifs in the N-terminus of BepE could be detected in their 
unphosphorylated state (peptide fragments encompassing amino acids 24-38, 
47-68, 83-99 and 100-122 in BepE). Moreover, three of these motifs were 
detected as being phosphorylated on their tyrosine in a proportion of 48, 88 and 
65 % (peptide fragments 24-38, 47-68, and 100-122). The fact that fragments 
encompassing the fifth putative tyrosine-phosphorylated motif could not be 
detected at all, might be due to technical reasons in the mass spectrometry 
analysis procedure. 
The analysis of the in vivo tyrosine-phosphorylated motifs in BepE is still 
ongoing and a first motif (…EPLYATVNK…) could be detected in its 
unphosphorylated, as well in its tyrosine-phosphorylated form (data not shown). 
 
 
BepE contains in its N-terminus ITIMs and ITSMs. To gather further 
indication for a function for these putative tyrosine-phosphorylation motifs, we 
used the blast tool (http://www.ncbi.nlm.nih.gov/BLAST/) and the ELM 
database (http://elm.eu.org/) and queried them with short (5-40 amino acids) 
peptide fragments of BepE. By these means, three distinct classes of motifs could 
be distinguished in the putative tyrosine-phosphorylated motifs of BepE: ITIMs 
and ITSMs, both present in subclasses of the IgG-like family of receptors (Fig. 
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4a), and a sequence (“…EPLYATVNK…”) similar to a known binding site for Csk 
in VE-Cadherin (Fig. 4b)  (21).  
Furthermore, the spacing for ITIM/ITSM tandems binding the two SH2 domains 
of phosphatases like SHP1 or SHP2 has been published to be in a range between 
15 and 30 aa (22), which is in accordance to the distance separating the 
ITIM/ITSM motifs in both tandems of BepE (26 and 22 aa, Fig. 4a). The 
consensus for the ITIM has been defined as Y/VxYxxV/L and for the ITSM as 
TxYxxV/L. The CD150 subfamily of receptors were shown to contain ITSMs with 
additionally a serine or threonine at position -4 in respect to the tyrosine 
(S/TxTxYxxV/L). This enables these receptors to bind additionally the adaptor 
proteins SH2D1A or EAT-2 to their ITSMs (16). This extended consensus also 
applies to the two ITSMs of BepE (SETIYTTV and SETLYAEV). The biological 
importance of the ITIMs/ITSMs as well as of the putative Csk binding site in the 
genus Bartonella is stressed by the high degree of conservation of these motifs 
between the BepE homologues of Bartonella henselae (BepE_Bh, accession-nr. 
Q6G2A4), Bartonella quintana (BepE_Bq, accession-nr. Q6FYV7 ) and 
Bartonella tribocorum (BepE_Bt, unpublished data, courtesy of H. Saenz) as 
shown in Fig. 4c. In contrast, the spacer sequence in between these motifs is very 
divergent, alike the spacer sequences of the various ITIM/ITSM-containing  
IgG-like receptors (Fig. 4a). 
 
BepE co-immunoprecipitates with Csk and SHP2 in a 
phosphorylation-dependent manner. To confirm the binding of Csk and 
SHP2 to BepE, we co-transfected a plasmid expressing FLAG tagged BepE in 
HEK293T cells together with a plasmid expressing c-Src or the empty vector 
control. Following immunoprecipitation with the FLAG antibody we probed the 
precipitate with anti-FLAG, anti-phosphotyrosine, anti-SHP2, and anti-Csk 
antibodies (Fig. 5). BepE is tyrosine-phosphorylated by the endogenous levels of 
tyrosine kinases present in the HEK293T cells. This tyrosine-phosphorylation 
can be dramatically increased by co-transfecting the cells with a vector 
expressing c-Src. Whereas already weakly tyrosine-phosphorylated BepE binds 
SHP2 and Csk, enhancing its tyrosine-phosphorylation also massively augments 
the amounts of SHP2 and Csk which are bound to BepE. 
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Mapping the binding sites of Csk and SHP2 in BepE by tyrosine to 
phenylalanine exchanges. By screening a phosphopeptide containing Y32 of 
BepE (“..EPLYATVNK…”) for cellular interaction partners using the SILAC 
method (23), Csk was shown to bind to this peptide in a tyrosine-
phosphorylation dependent manner (M. Selbach, P. Guye, M. Mann and C. 
Dehio, unpublished results).  To assess if this is the only binding site of Csk in 
BepE and to further characterize the binding sites of SHP2, we performed a 
systematic mutagenesis of the tyrosines in the putative phosphorylation motifs of 
BepE to phenylalanines. These FLAG-tagged mutants were then co-expressed in 
HEK293T cells with a vector expressing c-Src or an empty control. The c-Src co-
expression was used not to miss any SFK target motifs in BepE that might be 
weakly tyrosine-phosphorylated by endogenous amounts of the kinases. On the 
other hand, overexpressing c-Src might mask subtle differential or partial 
phosphorylation of these motifs, so we also co-expressed BepE with an empty 
vector control. Following lysis and immunprecipitation for the FLAG tag, we 
blotted and probed the precipitate for phosphotyrosine, Csk, FLAG tag and SHP2 
(Fig. 6).  
The BepE mutant in all five putative tyrosine-phosphorylation sites 
(BepE_FFFFF) did not show any detectable tyrosine-phosphorylation, in 
contrast to the wild type (BepE_YYYYY), and did neither bind Csk nor SHP2. In 
the mutant Y37F (BepE_FYYYY) the interaction with Csk is abolished (Fig. 6), 
demonstrating that Y37 mediates binding of Csk to BepE. Supporting this, 
exchanging all tyrosines of the ITIMs/ITSMs to phenylalanines and only 
preserving Y37 (BepE_YFFFF) is sufficient for Csk binding to BepE.  
The interaction of SHP2 to BepE is more complex. Whereas the exchange of the 
tyrosines in all ITIMs/ITSMs (BepE_YFFFF), abolished the interaction between 
BepE and SHP2, no complete loss of binding was visible by exchanging single or 
tandem tyrosines. The most striking reduction of SHP2 binding was visible in 
BepE_YFYYY without co-expression of c-Src, indicating of the first ITIM was the 
most crucial binding site for one of the SH2 domains of SHP2. 
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Discussion
 
ITIM-containing receptors play a crucial role in downregulating the activation of 
almost all known types of immune cells. Here, we report a protein secreted into 
infected cells by the pathogen Bartonella henselae, for which we have several 
lines of evidence that it is a molecular mimicry of such a receptor: (i) BepE has a 
membrane-proximal localization and also localizes to cell-cell contacts of 
infected cells. (ii) It contains in its N-terminus a Csk-binding motif and two 
ITIM/ITSM tandems with a spacing matching the one occurring in immune 
receptors. (iii) BepE is tyrosine-phosphorylated in these motifs by the SFK c-Src 
in vitro and in vivo, and binds upon phosphorylation Csk and SHP2. Data of 
ongoing work also indicate that Bh translocates this protein into dendritic cells 
and monocytes (P. Guye, S. Paoletti, G. de Libero and C. Dehio unpublished 
results). 
BepE is translocated into infected cells by the T4SS of Bh, as shown for HELA 
cells and HUVECs by means of immunofluorescence (Fig. 2). We also show that 
BepE is only tyrosine-phosphorylated in the infection process when secreted by 
wild-type Bh, as BepE from T4SS-defective Bh does not exhibit any tyrosine-
phosphorylation. This further supports the notion that BepE is a substrate of the 
VirB/VirD4 apparatus of Bh, as it must be translocated by the T4SS into the host 
cells for being tyrosine-phosphorylated by host cell kinases. It is important to 
note that most inhibitory immune receptors are thought to have a very weak or 
absent basal tyrosine-phosphorylation, which is enhanced upon engagement of 
the receptors. The constitutive phosphorylation of BepE indicates that this 
protein might induce signaling in the absence of an external stimulus, as one 
would expect by an effector mimicking a receptor to subvert the cell signaling. 
We reported earlier the translocation for some of the Bep proteins using the Cre 
recombinase reporter assay for translocation (CRAFT) (4). Interestingly, BepE 
was negative in this screen. This is probably due to its plasma membrane-
proximal localization (Fig. 2a), which interferes with the nuclear localization of 
the Cre-BepE fusion protein needed for the CRAFT readout. The same effect was 
observed for BepA, which also localizes to the plasma membrane of infected cells 
and is negative in the CRAFT assay, but positive for translocation in other 
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readouts, such as the calmodulin-dependent adenylate cyclase (cya)-reporter 
assay (M. Schmid, Chapter 3.3, this work).  Additionally, BepE localizes 
prominently to the cell-cell contacts of endothelial cells as shown by its co-
localization with VE-Cadherin in HUVECs (Fig. 2a). This peculiar localization 
provided crucial information concerning the putative functions of BepE in 
endothelial cells, which is currently investigated. Intriguingly, both localizations 
are not dependent on the tyrosine-phosphorylation of BepE, since the construct 
lacking the N-terminus localizes like the full-length protein. The weaker signal 
for this construct in contrast to wild-type BepE (Fig. 2a) might be due to a folding 
of the fusion protein which does not optimally expose the tag or due to a reduced 
stability of this truncated protein. 
Since it has been reported that the SFKs are responsible for tyrosine-
phosphorylation of other bacterial effectors as Tir or CagA, we tested in vitro and 
in vivo the effects of c-Src on BepE. While HIS-tag purified BepE is not tyrosine-
phosphorylated by incubating it together with ATP, the addition of recombinant 
active c-Src dramatically induces phosphorylation on tyrosine residues (Fig. 3). 
This assay rules out an autocatalytic phosphorylation of BepE.  To further assess 
the role of c-Src in vivo, we co-transfected HEK293T cells with a vector 
expressing FLAG-tagged BepE and one expressing c-Src. While the endogenous 
amounts of SFKs already tyrosine-phosphorylate BepE, the co-expression of  
c-Src further bolsters this effect (Fig. 5). Strikingly, in both the in vitro an in vivo 
kinase assays, tyrosine-phosphorylated BepE undergoes an apparent mass shift 
towards a higher mass, an effect which has also been reported for other tyrosine-
phosphorylated proteins (24).  
Bioinformatic analyses of the BepE protein sequence revealed five motifs in the 
N-terminus as putative tyrosine-phosphorylation sites. These motifs could be 
further classified as (i) putative Csk-binding sites, similar to a described  
Csk-binding site in VE-Cadherin (Fig. 4b, one motif), (ii) ITIMs (Fig. 4a, 4c, two 
motifs), and (iii) ITSMs (Fig. 4a, 4c, two motifs).  Furthermore, the spacing 
between the ITIMs and ITSMs in both tandems matched the consensus for these 
tandems in inhibitory immune receptors. The comparison of BepE from Bh, Bt 
and Bq supports the idea of an important biological function, as they are well 
conserved between the three species in contrast to the surrounding sequences 
(Fig. 4c).   
53
3.2 - Results 
The ITIMs and ITSMs motifs have been described in inhibitory immune 
receptors, where they bind upon tyrosine-phosphorylation phosphatases like 
SHP1, SHP2 and SHIP, or kinases like Csk and thereby suppress the activation of 
the immune cells.  
Mapping of the tyrosine-phosphorylation sites in BepE by mass spectrometry 
revealed three expected motifs which were tyrosine-phosphorylated in in vitro 
phosphorylated BepE: the Csk-binding site and the two ITIMs. Fragments 
covering the first ITSM could only be detected in their unphosphorylated state. 
This finding indicates that c-Src does not phosphorylate this ITSM, but probably 
another kinase does in vivo. We have indeed results indicating Csk being able to 
tyrosine-phosphorylate BepE in vivo (data not shown). As a model, c-Src might 
first phosphorylate BepE on its Csk-binding site, followed by the binding of Csk 
to this motif from where it then in turn tyrosine-phosphorylates the ITSM(s). 
Fragments covering the second ITSM could neither be detected in their tyrosine-
phosphorylated, nor in their unphosphorylated state, which is probably due to 
some technical problems associated to these peptide sequences. Additionally, 
three more peptides were detected that were tyrosine-phosphorylated by the  
c-Src kinase in vitro, albeit at a significantly lower efficiency (Table 1). A tyrosine 
to phenylalanine exchange mutant of BepE for the putative Csk-binding site and 
the two ITIM-ITSM tandems (BepE_FFFFF) showed in co-transfections with  
c-Src no detectable tyrosine-phosphorylation (Fig. 6), which indicates that the 
three additionally detected tyrosine-phosphorylated peptides are probably 
artifacts of this in vitro kinase assay. This might be due to the HIS-tag purified 
BepE exposing residues, which are not accessible in vivo, or c-Src kinase and/or 
kinase buffer conditions not optimally reflecting the in vivo conditions. Analysis 
of in vivo tyrosine-phosphorylated BepE revealed one tyrosine-phosphorylated 
motif (“..EPLYAVNK..”). This analysis is still ongoing for the other motifs. 
Having identified tyrosine-phosphorylation motifs also occurring in eukaryotic 
signaling proteins, we continued by analyzing interactions partners. We showed 
through co-immunoprecipitation that Csk and SHP2 interact with BepE in a 
phosphorylation-dependent manner in HEK293T cells (Fig. 5). Additionally, the 
binding of Csk to a phosphopeptide containing the “EPLYAVNK” sequence was 
confirmed by the SILAC method in collaboration with the laboratory of Matthias 
Mann (M. Selbach, P. Guye, C. Dehio, M. Mann, unpublished results). This 
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powerful novel technique might provide very useful in the retrieval of further 
interaction partners.  
Since BepE contains multiple phosphorylated tyrosines and putative tyrosine-
phosphorylation motifs, we systematically exchanged these tyrosines to 
phenylalanines and studied the effects of these exchanges on the binding of BepE 
to Csk and SHP2. We expressed the mutant forms of BepE in HEK293T cells by 
additionally facultatively co-expressing the c-Src kinase, immunoprecipitated it 
and probed the precipitate for Csk and SHP2 (Fig. 6). Csk binds to the most  
N-terminal tyrosine-phosphorylation motif of BepE, which does not match the 
consensus of an ITIM or ITSM pattern, but is similar to the Csk-binding site of 
VE-Cadherin. The binding of SHP2 is more elusive. Clearly, the binding of SHP2 
to BepE can be completely abrogated by mutating the four tyrosines of the two 
ITIM/ITSM tandems to phenylalanines. Most SHP2 binding is lost by mutating 
Y64 and Y106, Y64 having a more prominent role in this effect. This might 
indicate a preference for SHP2 to bind both ITIM motifs with its two SH2 
domains, but still having some residual lower affinity for the other ITIM/ITSM 
combinations. Additionally, we also showed a differential phosphorylation of the 
motifs in vitro by the means of mass spectrometry (Table 1), and in vivo by 
western blotting (Fig. 6), indicating that some motifs like the N-terminal first 
ITIM are preferentially phosphorylated, and therefore can bind more SHP2. 
While the binding of only one SH2 domain of SHP2 to BepE may be a possibility, 
binding of both domains is needed to achieve full phosphatase activity (25). This 
might of course also be achieved by having two BepE proteins in close contact, 
with each offering one binding site for an SH2 domain. The complexity of the 
system is further enhanced by the presence of two ITSMs. These motifs were 
shown to bind to adapter proteins such as SAP or EAT-2, and could therefore a.) 
switch the signaling mode from inhibitory to activatory by recruiting further 
phosphatases or kinases, and/or b.) regulate the accessibility of dual/single SH2-
containing phosphatase to the ITIMs/ITSMs (17). The binding of these adapters, 
which are only expressed in hematopoietic cell lines is currently being 
investigated, and might shed light on how BepE could act as a repressor in one 
cell type and as an activator in another one.  
The sequence similarities, the localization, and the interaction partners of BepE 
suggest that this protein mimicks inhibitory immune receptors. The subversive 
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potential of such receptor mimicry in the immune cells is huge. Translocated into 
NK cells or CD8+ T-cells, it might inhibit the killing of infected cells (26, 27), in 
CD4+ T-cells it could disturb the activation of B-cells and macrophages (27). In  
B-cells inhibitory receptors were shown to downmodulate their activation upon 
ligation of antigens to their BCR (28). In monocytes some of these receptors were 
shown to suppress the activation of the TLR-2 and TLR-4 pathways, 
subsequently inhibiting the TNFα secretion (29). Expression of inhibitory 
receptors on DCs concomitantly with a certain antigen induces tolerance of the 
immune system to this antigen, by anergizing the respective CD4+ T-cell clones 
(30). This mechanism could by used by a pathogen to specifically induce 
tolerance to its antigens in a host, without comprising the immune response to 
other pathogens. 
The binding of SHP2 and Csk by their SH2 domain(s) to BepE also promotes the 
understanding of BepE’s functions in the context of endothelial cells. The  
co-localization, and the similarity of the Csk-binding site of BepE to VE-Cadherin 
is currently investigated in our in vitro HUVEC models, as this site has been 
shown in VE-Cadherin to be crucial in mediating the contact-dependent 
inhibition of cell growth (21). The association of Csk over its SH3 domain with 
the tyrosine phosphatase PEST and their binding as a complex to Paxillin, where 
they dephosphorylate various proteins building up the focal adhesions, affects 
the motility of the cells (31, 32). Interfering with this contact inhibition and/or 
the cell motility by BepE may be one of the factors promoting the bacillary 
angiomatosis.  
A further mode for remodeling the structure of the endothelium in vivo is 
achieved by involving the immune system. Endothelial cells express MHC class I 
and II complexes and were shown to interact with and present antigens to 
circulating T-cells. This interaction is bi-directional, as circulating activated T-
cells can influence the signaling and behavior of endothelial cells, as for example 
the formation and remodeling of blood vessels (33). This signaling might be 
disturbed by a protein mimicking the inhibitory immune receptors and attenuate 
the activation of the cells involved. The sparse knowledge concerning antigen 
presentation by endothelial cells, and the mechanisms underlying their 
interactions with T-cells leaves us regrettably to only speculate about this.   
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Further characterization of the functions of BepE should give us completely new 
insights about how highly adapted pathogens survive, subvert and hide in their 
hosts, possibly even elucidating diseases which were not associated with 
pathogens up to now. 
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Materials and Methods 
 
Bacterial strains and growth conditions. The bacterial strains used in this 
study are listed in Table S1 of the Supplemental Material. Bartonella henselae 
were grown on Columbia agar plates containing 5% defibrinated sheep blood 
(CBA plates) at 35°C and 5% CO2 for 2-4 days. Strain RSE247, a spontaneous 
streptomycin-resistant strain of ATCC 49882T (34) served as wild-type in this 
study. When indicated, media were supplemented with 30 μg/ml kanamycin, 100 
μg/ml streptomycin, 10 μg/ml gentamicin, and/or 500 μM isopropyl-β-D-
thiogalactoside (IPTG). E. coli strains were cultivated in Luria-Bertani liquid 
medium (LB) or on Luria-Bertani agar on plates (LA) at 37°C overnight. When 
indicated, media were supplemented with 50 μg/ml kanamycin, 200 μg/ml 
ampicillin, 20 μg/ml gentamicin, 500 μM IPTG, and/or 1 mM diaminopimelic 
acid (DAP). 
 
Cell lines and culture conditions. HUVECs were isolated as  described (34). 
The embryonic kidney cell line HEK293T and HUVECs were cultured as 
described (3). 
 
DNA manipulations. Plasmids used in this study are listed in Supplementary 
Material Table S1, primers are listed in Supplementary Material Table S2.  
 
Plasmid for expression of FLAG-BepE. The plasmid expressing FLAG-BepE 
was built as follows: Full length bepE was amplified with the primer pair 
prPG101 and prPG101 from chromosomal DNA of RSE247 as template. Using the 
flanking NdeI-sites, the fragment was ligated into previously NdeI-cut pPG100. 
 
Plasmid for expression of proteins without an epitope tag. For constructing 
vector pPG110 expressing native proteins, the oligonucleotide primers prPG90 
and prPG91 were used to amplify a 0.4 kb fragment from pRS40 template DNA. 
Using flanking SacI sites the generated fragment was inserted into the 
corresponding site of pRS40. Next, a 1.67 kb fragment containing the complete 
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bepD gene and an N-terminal MYC tag was amplified using oligonucleotide 
primers prPG141 and prPG145 and chromosomal DNA of RSE247 as template. 
Using flanking NdeI-sites the amplified fragment was ligated into the 
corresponding site of pPG110, yielding pPG184. The empty MYC tag expression 
vector, pPG180, was generated by cutting out bepD with NdeI from pPG184, and 
religating the vector.   
 
Plasmid for expression of MYC-BepE. By excising full length bepE from 
pPG105 with NdeI and inserting it into the respective sites in pPG180, the 
MYC::BepE expressing vector, pPG185, was constructed. The vector expressing 
the two C-terminal BID domains of BepE without the N-terminus, pPG172, was 
constructed by PCR amplifying a fragment of 1 kb from pPG105 with the primers 
prPG148 and prPG149.  After digesting the fragment with NdeI, it was inserted in 
the respective site of pPG180. 
 
Plasmid for expression of HIS-BepE. Full-length bepE was amplified using 
the primer pair prPG83 and prPG84 from chromosomal DNA of RSE247 as 
template. Following digestion of the fragment with XhoI and BamHI, it was 
ligated into the respective sites of pET15b. 
 
Tyrosine to phenylalanine exchange mutants in BepE. To exchange the 
putatively phosphorylated tyrosines to phenylalanines in the N-terminus of 
BepE, we applied megaprime PCR to reamplify the sequence coding for BepE 
from pPG185 or from the respective mutants as shown in Table S2 of the 
Supplementary Materials. Briefly, using prPG190 and prPG191 binding on the 
plasmid pPG185 and two corresponding primers annealing to the site to be 
mutated, two fragments with a sequence overlap in the mutation site were 
amplified by PCR. In a second step, these two fragments were joined by 
megaprime PCR using prPG190 and prPG191, yielding a fragment of 2.1 kb. This 
fragment was then cut with NdeI, and inserted into the previously NdeI-cut 
pPG180 vector. The following mutants were generated in a first round using 
pPG185 as a template: Y37F (BepE_FYYYY), Y64F (BepE_YFYYY), Y91F 
(BepE_YYFYY), Y106F (BepE_YYYFY), Y129F (BepE_YYYYF) by using 
prPG192/prPG193, prPG194/prPG195, prPG204/205, prPG206/207, and 
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prPG196/197 respectively. In a second round, Y64F (BepE_YFYYY) was used as a 
template to generate Y64F;Y106F (BepE_YFYFY), Y91F (BepE_YYFYY) to 
generate Y64F;Y91F (BepE_YFFYY), and Y91F;Y129F (BepE_YYFYF), Y129F 
(BepE_YYYYF) to generate Y106F;Y129F (BepE_YYYFF). Finally, in three 
sequential mutation rounds, using Y64F;Y106F (BepE_YFYFY), I generated  
Y64F;Y91F;Y106F (BepE_YFFFY), Y64F;Y91F;Y106F;Y129F (BepE_YFFFF), and 
Y37F;Y64F;Y91F;Y106F;Y129F (BepE_FFFFF). 
The sequences encoding the different BepE mutants were then reamplified by 
PCR from their respective bacterial shuttle vectors using prTR15 and prTR16, cut 
with NotI and BamHI, and ligated into the corresponding sites of the pFLAG-
CMV2 plasmid, yielding the mutant panel in the eukaryotic expression vector. 
 
Immunocytochemical stainings and immunoprecipitation. HUVEC and 
HELA were infected with Bh strains at a MOI of 150 bacteria per cell for 48 
hours. Subsequently, they were fixed in 3.7% paraformaldehyde and stained for 
F-actin (TRITC-Phalloidin, Sigma, St. Louis, MO/USA), MYC-tagged BepE 
(mouse anti-MYC, Invitrogen, Carlsbad, CA/USA), VE-Cadherin (rabbit anti-VE-
Cadherin, Bender MedSystems, Burlingame, CA/USA), or total bacteria as 
described (3). Pictures were acquired with a Leica DM-RXE confocal microscope. 
Immunoprecipitation and Western blotting were performed as described (4). 
 
Transfection of HEK293T cells. Subconfluent (2.5 million cells) HEK293T 
cells in 8 cm cell-culture dishes were transfected with a total of 2.5 μg DNA 
following the protocol “Calcium phosphate−mediated transfection of eukaryotic 
cells with plasmid DNAs” (35). After 12 hours, the cell culture media was 
replaced and the cells kept in culture for additional 24 hours. Harvesting and 
immunoprecipitation was performed as described (4).
 
In vitro / in vivo phosphorylation and mass spectrometry analysis. 
Purified HIS-tagged BepE was incubated with recombinant active c-Src kinase 
(Upstate, Charlottesville, USA) in phosphorylation buffer (33 mM TrisHCl pH 
7.2, 40 mM MgCl2, 8 mM MnCl2, 700 μM EGTA, 80 μM sodium vanadate, 500 
μM ATP) at 30 °C for 60 minutes.   
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Transfected FLAG-BepE from HEK293T cells was immunoprecipitated as 
described (4) and washed five times in wash buffer (50 mM TrisHCl pH 7. 4, 75 
mM NaCl) to remove residual detergents. The anti-FLAG agarose bead pellet 
containing the precipitated proteins was then incubated for 5 minutes on ice in 
100 μl low pH buffer (36) (0.1 M Glycine, pH 2.5) to dissociate the FLAG tag 
from the antibody and centrifuged for 1 minute at 4500 g. For neutralizing the 
eluated proteins, we immediately removed the supernatant following 
centrifugation, and added 40 μl neutralization buffer (0.2 M TrisHCl pH 9.0). 
The in vitro and in vivo phosphorylated proteins were then digested with the 
proteases Trypsin or V8 after they had been dialyzed against 0.1 M NH4HCO3. 
The digests were stopped by adding 1/10th of the volume 10% acetic acid to. The 
resulting peptides were analysed by capillary liquid chromatography tandem MS 
(LC-MS/MS) using a Magic C18 100 µm internal diameter, 10 cm HPLC column 
(Spectronex, Basel, Switzerland) connected on line to a hybrid Finnigan Orbitrap 
instrument (ThermoFinnigan, San Jose, CA, U.S.A.). A linear gradient from 5 to 
75% B [0.1% acetic acid and 80% (v/v) acetonitrile in water]  in A (0.1% acetic 
acid and 2% acetonitrile in water) in 60 min was delivered with a Rheos 2200 
HPLC system (Flux, Basel, Switzerland) at 100 µl/min. A precolumn flow splitter 
reduced the flow to approx. 300 nl/min. 2 µl of the peptides were introduced into 
the injection loop of the MS. The eluting peptides were ionized by electrospray 
ionization, detected and the peptide ions were automatically selected and 
fragmented by collision induced dissociation (MS/MS) in the ion-trap. Individual 
MS/MS spectra were compared against the protein sequence of BepE using the 
TurboSequest software. The fragment spectrum of those peptides that had a 
mass shift of 80 Da were manually inspected to unambiguously assign the 
phosphorylated tyrosine. 
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Table S1: Bacterial strains and plasmids used in this study 
 
Strain or plasmid Genotype or relevant characteristics Reference  
 
Plasmids 
 
pRS40  vector for expression of (4) 
 NLS::Cre::MobA fusion proteins 
pPG100 E.coli-Bartonella shuttle vector,  (4) 
 encoding a short FLAG tag 
pPG110 E.coli-Bartonella shuttle vector,   this study 
 for tag-less expression  
pPG180 E.coli-Bartonella shuttle vector,  this study 
 encoding a short MYC  tag 
pET15b vector for expressing HIS-tag tagged  Novagen, Madison 
 proteins in the pET system   
pPG125 encoding HIS::BepE, derivative of pET15b 
pPG105 encoding FLAG::BepE this study 
pPG184 encoding MYC::BepD this study 
pPG185 encoding MYC::BepE_WT (wildtype) this study 
pPG185.M2 encoding MYC::BepE_FYYYY this study 
pPG185.M4 encoding MYC::BepE_YFYYY this study 
pPG185.M16 encoding MYC::BepE_YYFYY this study 
pPG185.M20 encoding MYC::BepE_YFFYY this study 
pPG185.M32 encoding MYC::BepE_YYYFY this study 
pPG185.M36 encoding MYC::BepE_YFYFY this study 
pPG185.M52 encoding MYC::BepE_YFFFY this study 
pPG185.M64 encoding MYC::BepE_YYYYF this study 
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 Table S1 continued 
 
Strain or plasmid Genotype or relevant characteristics Reference  
 
pPG185.M80 encoding MYC::BepE_YYFYF this study 
pPG185.M96 encoding MYC::BepE_YYYFF this study 
pPG185.M116 encoding MYC::BepE_YFFFF this study 
pPG185.M118 encoding MYC::BepE_FFFFF this study 
 
 
pCMV-FLAG2 eukaryotic expression vector, Eastman Kodak,
  encoding a short 
FLAG tag New Haven  
  
pTR1173 encoding FLAG::BepE_YYYYY (wild-type) this study 
pPG1173.M2 encoding FLAG::BepE_FYYYY this study 
pPG1173.M4 encoding FLAG::BepE_YFYYY this study 
pPG1173.M16 encoding FLAG::BepE_YYFYY this study 
pPG1173.M20 encoding FLAG::BepE_YFFYY this study 
pPG1173.M32 encoding FLAG::BepE_YYYFY this study 
pPG1173.M36 encoding FLAG::BepE_YFYFY this study 
pPG1173.M52 encoding FLAG::BepE_YFFFY this study 
pPG1173.M64 encoding FLAG::BepE_YYYYF this study 
pPG1173.M80 encoding FLAG::BepE_YYFYF this study 
pPG1173.M96 encoding FLAG::BepE_YYYFF this study 
pPG1173.M116 encoding FLAG::BepE_YFFFF this study 
pPG1173.M118 encoding FLAG::BepE_FFFFF this study 
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Table S1 continued 
 
Strain or plasmid Genotype or relevant characteristics Reference  
 
 
pCB6 empty eukaryotic expression vector (37) 
pCD211 eukaryotic expressing vector,  derivative of pCB6, (37) 
 encoding chicken c-Src  
 
  
E. coli strains 
 
NovaBlue endA1 hsdR17(r K12–m K12+) supE44 thi-1 recA1 Novagen, Madison
  gyrA96 relA1 lac[F’ 
proA+B+ lacIqZΔM15::Tn10 (TcR)]  
     
β2150  F' lacZDM15 lacIq traD36 proA+B+ thrB1004 pro (34) 
 thi strA hsdS lacZΔM15 ΔdapA::erm (ErmR) pir 
  
Rosetta (DE3) F– ompT hsdS (r – m –) gal dcm (DE3)  Novagen, Madison
  
 pRARE2 (CamR) 
 
B. henselae strains 
 
RSE242 ΔvirB4 mutant, derivative of RSE247 (3) 
RSE247 Spontaneous SmR strain of ATCC 49882T, (3) 
 serving as wild-type 
TRB106 ΔbepB-G mutant, derivative of RSE247 (4) 
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Table S1 continued 
 
Strain or plasmid Genotype or relevant characteristics Reference  
 
 
PGB44 RSE247 containing pPG105 this study  
PGB45 RSE242 containing pPG105 this study 
PGB59 RSE247 containing pPG100  this study 
PGB55 RSE242 containing pPG100 this study 
PGE76 TRB106 containing pPG180  this study  
PGE77 TRB106 containing pPG185  this study  
PGH01 TRB106 containing pPG185.M2  this study 
PGH02 TRB106 containing pPG180.M4 this study 
PGH03 TRB106 containing pPG180 .M16 this study 
PGH04 TRB106 containing pPG180 .M20 this study 
PGH05 TRB106 containing pPG180 .M32 this study 
PGH06 TRB106 containing pPG180 .M36 this study 
PGH07 TRB106 containing pPG180 .M52 this study 
PGH08 TRB106 containing pPG180 .M64 this study 
PGH09 TRB106 containing pPG180 .M80 this study 
PGH10 TRB106 containing pPG180 .M96 this study 
PGH11 TRB106 containing pPG180 .M116 this study 
PGH12 TRB106 containing pPG180 .M118 this study 
PGH18 TRB106 containing pPG172 this study 
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Table S2: Oligonucleotides used in this study 
 
Name Sequence Restriction sites 
 
prTR15 ATAAGAATGCGGCCGCGATGAAAAGAAATCAACCACCCC NotI 
prTR16 CGGGATCCTTAGATGGCGAAAGCTATTGCC BamHI 
prPG83 CCGCTCGAGATGAAAAGAAATCAACCACCC XhoI 
prPG84 CGGGATCCTTAGATGGCGAAAGCTATTGC BamHI 
prPG90 CGCGAGCTCTTTAAGAAGGAGATATACATATGGG SacI, NdeI 
 GATGCCTGGCAGTTTAT 
prPG91 CGCGAGCTCTAAATCAGAACGCAGAAGCG NdeI 
prPG100 GGAATTCCATATGAAAAGAAATCAACCACCC NdeI 
prPG101 GGAATTCCATATGTTAGATGGCGAAAGCTATTGC NdeI 
prPG141 CGCGCTTATTAATGGAACAAAAACTTATTTCTGAA AseI, NdeI 
 GAAGATCTTCATATGAAAAAAAATCGACCATCCCCT 
prPG142 CGCGCTTATTAATCATATGTTACATACCAAAGGCCA AseI, NdeI 
 TTCC 
prPG148 GGAATTCCATATGGTCGACTACCACGCCGGATCCAGCAC NdeI, SalI,  
 AATACCATCTCTAACAAGAGAG BamHI 
prPG149 GGAATTCCATATGTTAGATGGCGAAAGCTATTGC NdeI 
prPG190 GCTCCGCCATCGCCGCT 
prPG191 GGATTTGAACGTTGCGAAGC 
prPG192 CACCGCAACCAGAACCTTTATTTGCAACGGTGAACA 
 AAAGACC 
prPG193 GGTCTTTTGTTCACCGTTGCAAATAAAGGTTCTGGTT 
 GCGGTG 
prPG194 AGCCAACAGGAAGAAGTCGTATTTGCAGCGCTTGAT
 TTTGAAAATAGATC 
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Table S2 continued 
 
Name Sequence Restriction sites 
 
 
prPG195 GATCTATTTTCAAAATCAAGCGCTGCAAATACGACTT 
 CTTCCTGTTGGCT 
prPG196 ATCCGGCAAGCGAAACTTTATTTGCAGAAGTTGCTAT 
 GCAAAGCAC 
prPG197 GTGCTTTGCATAGCAACTTCTGCAAATAAAGTTTCGC 
 TTGCCGGAT 
prPG204 GAATCTAGAAAGCGAAACTATATTTACGACAGTTTCTT 
 CTCAAAG 
prPG205 CTTTGAGAAGAAACTGTCGTAAATATAGTTTCGCTTTC 
 TAGATTC 
prPG206 CAACACAAGCAGAAATACTCTTTGCAGATGTCACTC 
 ACAC 
prPG207 GTGTGAGTGACATCTGCAAAGAGTATTTCTGCTTGT 
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Tables and Figures 
 
Table. 1. Mapping the phosphorylated tyrosines by the means of mass 
spectrometry. HIS-affinity purified, and in vitro phosphorylated BepE was 
digested with proteases and subjected to mass spectrometry analysis as described 
in Materials and Methods. The sequence of the detected fragments containing 
the putative phosphorylation sites and their positions in BepE are indicated in 
the first and second column, the enzyme used for their digestion in the third. The 
measured masses of the fragments in their unphosphorylated and in their 
tyrosine-phosphorylated state (mass and pY-mass) are in the fourth and fifth 
columns. The percentage (pY %) indicates how much of a given fragment was 
detected to be tyrosine-phosphorylated vs. the total amount (counts) of this 
fragment. For one fragment, its mass could not be detected in its tyrosine-
phosphorylated form (not detectable, n.d.). 
 
Fig. 1. BepE becomes tyrosine phosphorylated after VirB4-dependent 
translocation into HUVEC. Total protein extracts of HUVECs uninfected (lane 1) 
or infected with virB4 (lane 2), wild type (lane 3), virB4/pPG105 (lane 4), or 
wild type/pPG105 (lane 5) were prepared. FLAG-BepE encoded by pPG105 was 
immunoprecipitated with anti-FLAG antibodies, separated by SDS/PAGE, and 
immunoblotted with anti-FLAG (left) or anti-phosphotyrosine antibodies (right). 
 
 
Fig. 2.  BepE localizes to the membrane of HELA cells and to the membrane and 
cell-cell contacts of infected HUVECs. (A) Full-length MYC tagged BepE 
(MYC::BepE) and the two MYC tagged C-terminal BID domains (MYC::BIDs). 
The (+++) indicates the positively charged tail sequence C-terminally to the BID, 
required for the VirB/VirD4-dependent translocation (B) The two C-terminal 
BID domains of BepE are sufficient to achieve this localization. HELA cells were 
infected for 48 h at a MOI of 150 bacteria per cell, fixed, permeabilized, and 
stained for f-actin (red), MYC-tag (green), and total bacteria (blue).  (1) 
uninfected cells, (2) empty vector control,  (3) MYC::BepE, (4) MYC::BIDs. The 
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scale bar represents 20 μm. (B) HUVECs were infected for 48 h with 150 bacteria 
per cell, fixed, permeabilized, and stained for VE-Cadherin (red), MYC-tag 
(green), and f-actin (blue).  (1) uninfected cells, (2) empty vector control,  (3) 
MYC::BepE, (4) MYC::BIDs.  The scale bar represents 20 μm. 
 
 
Fig. 3.  BepE is tyrosine-phosphorylated in vitro by the c-Src kinase. HIS-tag 
purified BepE was incubated with recombinant purified active c-Src kinase and 
ATP, separated by SDS/Page stained with Coomassie or immunoblotted with 
anti-FLAG or anti-phosphotyrosine antibodies. 
 
 
Fig. 4. BepE contains similar tyrosine-phosphorylation motifs to the ones in 
eukaryotic inhibitory immune receptors and VE-Cadherin and is conserved in 
these motifs between different Bartonella species. (A) BepE contains two 
ITIM/ITSM tandems with similar sequence conservation and spacing as in 
immunotyrosine inhibitory receptors (BepE_Bh: Q6G2A4; LIRB1: Q8NHL6; 
LAIR-1: Q8NHJ6; CD33: P20138; PD-1: Q15116; NTB-A: Q96DU3; CD244: 
Q9BZW8; CD31: P16284; SHPS-1: P78324) (B) BepE contains a putative binding 
site for Csk, as the similarity to the known binding site of Csk in the human VE-
Cadherin (accession-nr. P33151) suggests. (C) BepE of Bartonella henselae, 
Bartonella quintana and Bartonella tribocorum show a high degree of 
conservation in the putative Csk binding sites and the ITIM/ITSM tandems, 
suggesting a evolutionary pressure to maintain these motifs. The spacer 
sequences between the motifs is highly variable, alike the spacer sequences in 
between the ITIM/ITSM motifs of immunotyrosine inhibitory receptors (B). 
 
Fig. 5. BepE binds Csk and SHP2 in a phosphorylation dependent manner. 
HEK293T cells were transfected with a vector expressing FLAG-BepE (pTR1173) 
or the empty vector (pCMV-FLAG2) and with a plasmid expressing c-Src 
(pCD211) or the respective empty vector (pCB6). Following anti-FLAG 
immunoprecipitation, separation by SDS/PAGE and western blotting, we probed 
the membranes with anti-FLAG, anti-phosphotyrosine (pY), anti-Csk and anti-
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SHP2 antibodies. Lane 1: pCMV-FLAG2 and pCB6, Lane 2: pTR1173 and pCB6, 
Lane 3: pCMV-FLAG and pCD211, Lane 4: pTR1173 and pCD211. 
 
Fig. 6. Mapping the binding sites of Csk and SHP2 in BepE. HEK293T cells were 
transfected with vectors expressing FLAG-tagged tyrosine to phenylalanine 
mutants of BepE (Table 2 in Supplementary Materials) together with a plasmid 
expressing c-Src or the empty control vector and probed as described in Fig 5.   
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peptide 
residue 
(aa) 
 
cutting 
enzyme 
 
mass 
(Da) 
pY-mass 
(Da) 
pY 
(%) 
 
QREPYGQSAER 
 
13-23 Trypsin 1304.67 1384.64 17 
 
APSPQPEPLYAT
VNK 
 
24-38 Trypsin 1611.84 1691.8 48 
 
ELNKPLSQQE 
EVVYAALDFENR 
 
47-68 Trypsin 2592.29 2672.26 88 
 
SETIYTTVSS 
QSTTQAE 
 
83-99 V8 1832.84 n.d. n.d. 
 
ILYADVTHTPLH 
SKHTRRDPASE 
 
100-122 V8 2644.36 2724.33 65 
 
IVYGNSDVLK 
 
165-174 Trypsin 1107.6 1187.57 0.2 
  
Table 1 
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Additional manuscripts as co-author 
 
This chapter contains the abstracts of two manuscripts for which I am co-author. 
In the course of my Ph.D. thesis, my contributions to these studies has been 
mainly the construction of plasmids and bacterial strains required for the 
translocation of individual Beps into host cells. 
 
 
The two manuscripts describe how host cell signaling is subverted by Beps of 
Bartonella henselae other than the phopho-Beps described in the previous and 
next chapters. Two phenotypes previously associated to the VirB/VirD4 T4SS of 
Bartonella henselae, anti-apoptosis, and cytoskeletal rearrangements, could be 
directly associated to the effector proteins BepA and BepG, respectively. 
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Abstract  
 
The modulation of host cell apoptosis by bacterial pathogens is of critical 
importance for the outcome of the infection process. The capacity of Bartonella 
henselae (Bh) and Bartonella quintana (Bq) to cause vascular tumor formation 
in immunocompromized patients is linked to the inhibition of vascular 
endothelial cell (EC) apoptosis. Here, we show that translocation of BepA, a type 
IV secretion (T4S) substrate is necessary and sufficient to inhibit EC apoptosis. 
Ectopic expression in EC allowed mapping the anti-apoptotic activity of BepA to 
the BID domain, which as part of the signal for T4S is conserved in other T4S 
substrates. The anti-apoptotic activity appeared to be limited to BepA orthologs 
of Bh and Bq and correlated with (i) protein localization to the host cell plasma 
membrane, (ii) elevated levels of intracellular cAMP, and (iii) increased 
expression of cAMP-responsive genes. The pharmacological elevation of cAMP 
levels protected EC from apoptosis, indicating that BepA mediates anti-apoptosis 
by heightening cAMP levels by a plasma membrane-associated mechanism. 
Finally, we demonstrate that BepA mediates a marked protection of EC against 
cell death triggered by cytotoxic T-lymphocytes (CTL), suggesting a physiological 
context in which the anti-apoptotic activity of BepA contributes to tumor 
formation in the chronically infected vascular endothelium.   
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Abstract 
 
Uptake of the bacterial pathogen Bartonella henselae into human endothelial 
cells induces re-organization of the host-cell plasma membrane and re-
arrangement of the actin cytoskeleton, resulting in the internalization of bacterial 
aggregates by a unique structure termed invasome. In the present study, we 
report the identification and characterization of a novel bacterial effector protein 
mediating the sustained cellular changes leading to invasome formation. 
Moreover, we show that invasome-mediated uptake requires the action of Rho-
family small GTPases Cdc42 and Rac1 but not RhoA and that invasion not only 
leads to the rearrangement of pre-existing F-actin fibers but as well to localized 
actin polymerization as suggested by the requirement of Scar1/WAVE adaptor 
proteins and enrichment of the Arp2/3 complex at sites of invasome-mediated 
uptake. Finally, we present data indicating that invasome formation may 
represent a novel mechanism leading to internalization of bacteria but 
preventing fusion with the endocytic-lysosomal pathway. Taken together, our 
data suggest that invasome formation is a sophisticated, multi-step process of 
cellular invasion to establish an intracellular niche in endothelial cells permissive 
for persistent colonization of the vasculature. 
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Additional Work (unpublished) 
BepD and BepG as antigens in clinical cases of cat-scratch 
disease 
 
Since the Bep proteins are secreted into infected cells, they are candidates for 
being prominently exposed by the antigen-presentation machinery of these host 
cells. To test this hypothesis and the detection of the Beps by serology, I 
overexpressed some of the FLAG-tagged Beps and probed the total lysate of these 
cells with serum of patients 
with clinical symptoms of 
cat-scratch disease and a 
secondary anti-human 
antibody. Since Bh does 
not express the virB/bep 
loci on CBA plates, I could 
probe for the single Beps 
expressed with a FLAG-tag 
on a vector. As shown in 
Fig. 1, BepD and BepG are 
recognized by antibodies in 
the serum of a patient. 
Further refined, this 
finding could be used to 
develop a serology test. 
 
BepG 
BepD 
1 2 3 4 5 6 
Fig. 1. Total lysates of Bh expressing FLAG-tagged 1.) 
BepA, 2.) BepD, 3.) BepE, 4.) BepF, 5.) BepG, 6.) no Beps 
(wild-type) probed with serum of a patient with clinical 
symptoms of cat-scratch disease. 
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Expression and purification of HIS-tagged BepD 
For further studies, I purified BepD by overexpressing the protein in the pET15b 
system of E. coli BL21DE3, lysis by french press, and HIS-affinity purification 
over a Nickel-agarose column. The protein was subsequently eluted with 250 mM 
Imidazol, as shown in Fig. 2. 
 
 
 
 
 
 
 
 
Fig. 2. (A) Total lysate of E. coli BL21DE3 containing HIS_BepD, uninduced (lane 1), or induced 
with 500 μM IPTG (lane 2) for three hours, the arrow marks the size of HIS-tagged BepE. (B) 
Imidazol-eluted fractions from the Nickel-agarose column, containing HIS-BepD (fractions 2-4). 
1 2 1 2 3 4 
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Mapping tyrosine-phosphorylated sites in BepD 
To map the tyrosine-phosphorylation sites of BepD, I performed an in vitro 
phosphorylation reaction as described in the manuscript “Molecular mimicry of 
inhibitory immune receptors by the bacterial pathogen Bartonella”. 
Subsequently, Paul Jenö digested it with trypsin and analyzed the resulting 
fragments by MALDI-TOF. Two tyrosine-containing peptides phosphorylated by 
c-Src could be detected in BepD: APSPQAEPLYAQVNKPPR and 
TPSPQAEPLYAQVNKPPR (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.  HIS-tagged BepD incubated in the in vitro phosphorylation buffer without (A) or with c-
Src kinase.  Both fractions were subsequently digested with trypsin and the resulting fragments 
detected by mass spectrometry. The indicated sizes correspond to the peptides 
APSPQAEPLYAQVNKPPR and TPSPQAEPLYAQVNKPPR, in their unphosphorylated and 
tyrosine-phosphorylated state (+ 80 Dalton). 
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Tyrosine-phosphorylation of BepD results in a relocalization 
from the Triton X-100 soluble to the Triton X-100 resistant 
fraction 
 
Tyrosine-phosphorylated BepD exhibited a peculiar property: whenever the 
FLAG-tagged BepD was tyrosine-phosphorylated by co-expressed c-Src kinase in 
HEK293T cells, it could not be recovered in 1 % v/v Triton X-100 cell lysates by 
immunoprecipitation. A glance at the FLAG-tagged BepD content in the total 
lysate and in the unsoluble pellet of the Triton X-100 lysate showed that BepD 
became unsoluble in this lysis buffer upon tyrosine-phosphorylation (Fig. 4). A 
possible explanation for this insolubility is BepD localizing to lipid rafts. 
Additionally, BepD underwent a pronounced mass shift upon tyrosine-
phosphorylation as already shown (1). 
 
 
 
 
 
  
B A 
 0 0.02 0.2 1 2 0 0.02 0.2 1 2 μg c-Src 
  2 2 2 2 2 2 2 2 2 2 μg FLAG-BepD 
 
 
Fig. 4. BepD becomes unsoluble upon tyrosine-phosphorylation in a 1 % Triton X-100 lysate. (A) 
Total (SDS sample buffer) cell lysate probed for the FLAG-tag (BepD). (B) Unsoluble fraction (pellet) 
remaining after lysis with 1 % Triton X-100 probed for FLAG-tag (BepD). The amounts of transfected 
c-Src and FLAG-BepD expressing vectors are given below. 
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BepD does bind Csk in a tyrosine-phosphorylation dependant 
manner 
 
BepD contains in its N-terminus a putative tyrosine-phosphorylation motif which 
is very similar to the one binding Csk in BepE and VE-Cadherin, suggesting that 
also BepD could have Csk as an interaction partner. To test this, I co-transfected 
HEK293T cells with a vector expressing MYC-tagged BepE together with one 
expressing c-Src, lysed the cells, and immunoprecipitated with antibodies against 
the MYC-tag. The precipitate was then probed with an anti-Csk and a anti-MYC 
antibody. No IgG heavy chain (from the mouse anti-MYC antibody) is visible in 
the anti-Csk blot because we used a rabbit/anti-rabbit antibody for the detection 
there. BepD interacts with Csk in a phosphorylation-dependant manner, as 
shown in Fig. 5. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. BepD interacts with Csk in a tyrosine-phosphorylation dependent 
manner. MYC-BepD and c-Src were co-expressed, and 
immunoprecipitated with antibodies against the MYC-tag. 
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BepD binds SHP2 in a tyrosine-phosphorylation dependent 
manner  
 
As BepD and BepE contain putative tyrosine-phosophorylation motifs predicted 
by the Scansite software to bind to SH2 domains of SHIP/SHP2 phosphatases, 
we probed immunoprecipitated FLAG-BepD, FLAG-BepE, FLAG-BepF (kindly 
provided by T. Rhomberg) with an anti-SHP2 antibody. Clearly, BepD and BepE 
bound SHP2 in a tyrosine-phosphorylation dependent manner (Fig. 6), and as 
expected from the bioinformatic analysis, BepF does not. Interestingly, in 
HEK293T cells, BepF is highly tyrosine-phosphorylated  without co-transfection 
of c-Src, in contrast to BepD and BepE. This may indicate that BepF is tyrosine-
phoshorylated by another kinase, present and active in these cells. 
 
Fig. 6. SHP2 binds to BepD and BepE and not to BepF in a tyrosine-
phosphorylation dependent manner. We co-expressed FLAG-BepD, -BepE and 
BepF facultatively with c-Src, immunoprecipitated with antibodies against the 
FLAG-tag and probed the precipitate with an anti-SHP2 antibody.   
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c-Abl is the candidate kinase for BepF 
 
Multiple data indicate that c-Src is not the kinase of BepF.  Bioinformatic 
analysis by using the Scansite algorithm (2) propose c-Abl as the kinase of at 
least six of the seven putative tyrosine-phosophorylation motifs of BepF (Table 
1). Additionally, BepF is highly tyrosine-phosphorylated in HEK293T cells 
without co-expression of c-Src (Fig. 7). This tyrosine-phosphorylation is not 
increased by additional expression of c-Src. Moreover, by adding 10 μM of the c-
Abl inhibitor Imatinib Mesylate (Gleevec®) to the media of BepF transfected 
cells, tyrosine-phosphorylation of this protein was reduced by 75% in comparison 
to cells treated with the vehicle control alone (results not shown).  By using the 
SILAC method, we could show that the adapter protein Crk binds to at least one 
of these motifs  (“PQDSTPLYATPSPQQ”, M. Selbach, unpublished results) in an 
tyrosine-phosphorylation dependent manner. 
 
Table 1.  Scansite 
predicition for motifs 
in BepF tyrosine-
phophorylated by c-
Abl. The percentile 
value of 0.002 
signifies that this hit 
ranks in the best 
0.002% in a search 
space of 430914 
motifs, which is an 
exceptionally good 
value. 
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Fig. 7.  BepF is strongly tyrosine-phosphorylated by 
endogenous kinase levels in HEK293T cells. Co-
expression of c-Src does not increase this tyrosine-
phosphorylation, in contrast to BepD and BepE. The 
arrow marks the size of the IgG heavy chain. 
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BepE inhibits host-cell fragmentation 
 
To further assess the role of BepD and BepE in the infection process, I 
constructed non-polar in-frame mutants in Bh (ΔbepD, ΔbepE, ΔbepDEF), while 
ΔbepF was kindly provided by T. Rhomberg. By infecting HUVECs with these 
strains, a prominent phenotype for the ΔbepE and the ΔbepDEF mutant became 
evident, with the effect starting about 20-24 hours post infection, while no 
phenotype was visible for the ΔbepD or ΔbepF mutants in comparison to the 
wild-type bacteria. This assessment was done by time-lapse video microscopy 
and by immunofluorescence stainings of fixed cells. Whenever BepE was deleted 
from the wild-type Bh strain (ΔbepE or ΔbepDEF), the infected HUVECs became 
highly agitated, deformed, and fragmented multiple times (Fig. 8, Fig. 10). Most 
of these fragments did not carry a nucleus and got smaller by continuing 
fragmentation. The fragments erratically roamed on the substrate for a few hours 
and then came to a halt, possibly because they had used up all their energy. By 
providing BepE or only the two C-terminal BID domains of BepE in trans on a 
plasmid, the infected HUVECs behaved like infected with wild-type Bh, 
indicating that this effect was indeed mediated specifically by the BID domains of 
BepE (Fig. 8, Fig. 9) . Intriguingly, the ΔbepB-G or the ΔvirB4 mutant, defective 
in type IV secretion through the virB apparatus, did not exhibit such a 
phenotype, suggesting that either BepB, C or G, or another unknown, T4SS 
mediated effector is responsible for disturbing the cells, which can be 
counteracted by BepE. This effect was not further pursued, as it is not dependent 
on the tyrosine-phosphorylated N-terminus of BepE. The reason and 
mechanisms of this dramatic reaction in the endothelial cells is elusive. So 
further studies may provide very interesting findings on how cellular motility, 
focal adhesion turnover and/or cellular integrity is modulated.  
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Fig. 8. Lack of BepE in a secretion competent Bh strain induces fragmentation of the 
endothelial cells (24 hours post-infection). This effect is complementable by providing BepE in 
trans. The f-actin is colored in red, the MYC-tag green, and the bacteria in blue. 
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Fig. 9. The two BID domains of BepE are sufficient to inhibit the 
fragmentation of the endothelial cells, as shown 24 hours post-
infection. The red arrows indicate the beginning of fragmentation. 
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Fig. 10. The fragmention occurs between 24 and 36 hours post-infection. HUVECs were 
infected with the Bh mutant lacking bepE, and images were acquired by time-lapse 
microscopy. The white arrows indicate the beginning of the fragmentation of one cell, the 
yellow and red arrows further sub-fragmentation. The size bar  represents 100 μm. 
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4. Summary 
 
We identified in the first manuscript the secreted substrates of the VirB type IV 
secretion system in Bh and first biological effects of this apparatus on endothelial 
cells. Furthermore, we describe the domain mediating the secretion, which 
proved to be bipartite.  Additionally, we revealed by bioinformatics evolutionarily 
related translocation domains, which are also secreted by  
the T4SS of Bh, suggesting that this secretion system is able to transfer DNA into 
host cells. 
In the second manuscript we focus on the tyrosine-phosphorylated BepE protein, 
and show that it contains a binding site for the SH2 domain of Csk and  
ITIMs-TSMs tandems in its N-terminus, reminiscent of inhibitory immune 
receptors. BepE is, consistently with this finding, tyrosine-phosphorylated by 
SFKs in these motifs and subsequently binds to Csk and SHP2. In addition to its 
localization to the proximity of the membrane, BepE does also co-localize with 
VE-Cadherin in the cell-cell contacts of HUVECs. 
Having contributed to two more publications as a co-author, these two 
manuscripts are quickly presented by their abstracts in Chapter 3.3, illustrating 
the advances in elucidating the functions of two other Beps, BepA and BepG, in 
the infection process. 
In the last part, the additional unpublished work, I show that BepD is also 
tyrosine-phosphorylated by SFKs, whereupon it binds to Csk and SHP2, and 
furthermore relocalizes to a Triton X-100 insoluble fraction. In contrast, BepF 
seems to be tyrosine-phosphorylated by another group of kinases, probably from 
the Abl family. Moverover BepE inhibits by virtue of its double BID domains a 
dramatic fragmentation of infected cells, as shown by time-lapse microscopy.  
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5. Conclusions 
 
What are the substrates of the VirB/VirD4 T4SS of Bartonella 
henselae? 
 
Starting point for the first published report (“A bipartite signal mediates the 
transfer of type IV secreted substrates of Bartonella henselae into human cells”, 
Chapter 3.1) in my Ph.D. thesis was the finding that the VirB/VirD4 T4SS of B. 
tribocorum was essential for the pathogen to establish an intra-erythrocytic 
infection in an animal model (1). Additionally, at that time, unpublished data 
indicated that many phenotypes which were already known for B. henselae 
infecting HUVECs, as anti-apoptosis (2), cytoskeletal rearrangements (3) and 
pro-inflammatory activation (4),  were dependent on a intact VirB/VirD4 T4SS 
(5). These findings were suggestive of substrates being translocated through the 
VirB/VirD4 T4SS of Bartonella into the host cells. 
Sequencing 23 kb downstream of the virB locus of B. henselae revealed a 
coupling protein (virD4), and seven genes encoding at least one common C-
terminal domain. The proteins encoded by these seven genes were later termed 
Bartonella exported proteins (Beps), the common C-terminal domain they 
contain Bartonella intracellular delivery (BID). By constructing a Hidden 
Markov Model from these BID domains and querying protein databases, we 
found similar domains in the C-terminus of relaxases from conjugative plasmids 
in the  
α-proteobacteria. We showed exemplarily that the C-terminus of the TraA 
relaxase from the AvhB/TraG conjugation system in A. tumefaciens – one of the 
top hits in the database search - could still be translocated by the VirB/VirD4 
T4SS of B. henselae. Both these findings support that the BID domain evolved 
from conjugative relaxases, in parallel with the T4SS of B. henselae. Full-length 
relaxases bind covalently to plasmid DNA and mediate its transfer through 
T4SSs. This allows the fascinating speculation that the VirB/VirD4 T4SS of 
Bartonella could be used to export DNA by those means in vivo into host cells.  
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To demonstrate exemplarily the translocation of the Beps through the 
VirB/VirD4 T4SS, we fused a FLAG-tag to the N-terminus of BepD and could 
show that BepD is translocated into infected endothelial cells in a VirB/VirD4 
T4SS-dependent manner, whereupon it localizes to the cytoplasm of these cells 
and is tyrosine-phosphorylated by host-cell kinases. The precise experimental 
delineation of the domain needed for translocation was made possible by the 
development of the Cre-recombinase reporter assay for translocation (CRAFT), 
which showed the translocation domain to be bipartite. In addition to the BID 
domain, a short, positively charged C-terminal amino acid sequence was needed 
for an effective delivery of proteins.   
Non-polar deletions of all the ORFs encoding the Beps abolished the ability of Bh 
to induce a variety of host-cell phenotypes, suggesting that these proteins elicit 
biological effects in their eukaryotic target cells.  This finding was the fundament 
for the two Manuscripts presented in Chapter 3.3, "A translocated protein of the 
vascular-tumor inducing pathogen Bartonella protects human vascular 
endothelial cells from Apoptosis" and “Subversion of host cell cytoskeletal 
function during invasome-mediated uptake of Bartonella henselae into human 
endothelial cells”. In each of these two manuscripts, a major phenotype of the 
infection of HUVECs by B. henselae is shown to depend on a single Bep. While 
BepA inhibits the apoptosis of endothelial cells, BepG does induce massive 
cytoskeletal rearrangements. Interestingly, it is the BID domain of BepA which 
mediates the anti-apoptotic activity in the host cell as well as the localization of 
this protein to the plasma membrane. This involvement of the BID in localization 
and function in the host cell holds also true for BepE, as we showed that the two 
BID domains of this protein are crucial for its localization (Chapter 3.2), and to 
inhibit the fragmentation of infected endothelial cells (Chapter 3.4). 
 
 
Many interfaces for interactions over phosphotyrosines 
  
Of the seven Bep proteins, three contain putative tyrosine-phosphorylation 
motifs in their N-terminus. We showed that both BepD and BepE are tyrosine-
phoshorylated by the c-Src kinase. Because of their similar substrate specificities 
and their variable expression levels depending on the cell type, any member of 
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the SFK could potentially be the kinase of BepD and BepE in vivo. Bioinformatics 
and preliminary experiments suggest c-Abl as the kinase of BepF. As Crk was 
shown to bind BepF, and one of the functions of Crk has been described to 
activate c-Abl, one might speculate that a positive activation loop takes place 
once BepF has been phosphorylated, which would bind and activate increasing 
amounts of the c-Abl kinase to BepF through Crk.  Whereas c-Abl has been 
implicated in the invasion process of other pathogens (6), the exact function of 
BepF in Bartonella still remains to be uncovered. 
BepD localizes in immunofluorescence stainings to a cytoplasmic vesicular-like 
compartment. Additionally, it localizes upon its tyrosine-phosphorylation to a 
Triton X-1oo insoluble fraction, and binds SHP2 and Csk. Lipid rafts are 
prominently associated to Triton X-100 insoluble fractions, and future studies 
might show BepD interfering with the signaling in these rafts. 
I subsequently focused on BepE, for which bioinformatics revealed an intriguing 
similarity to inhibitory immune receptors of mammals.  This resulted in the 
second manuscript “Molecular mimicry of inhibitory immune receptors by the 
bacterial pathogen Bartonella” (Chapter 3.2). BepE contains two C-terminal BID 
domains which mediate the localization of this protein to the plasma membrane 
of HELA cells and to the plasma membrane and cell-cell contacts in endothelial 
cells, as shown by a co-localizing immunofluorescence staining with VE-Cadherin 
in HUVECs. This peculiar localization is very intriguing, and might modulate the 
cell-cell contact strength or the contact inhibition which is crucial in endothelial 
cells. Recently, a publication demonstrated that VE-Cadherin contains in its 
intracellular domain a binding site for the SH2 domain of Csk, the binding of Csk 
to this site being crucial for the contact inhibition of cell growth (7). We 
identified a very similar motif in the N-terminus of BepE which did also bind 
Csk. The co-localization and a similar tyrosine-phosphorylation motif binding the 
same protein makes this finding a good starting point for investigating the 
functions of BepE in the endothelium. 
BepE contains in addition to this Csk-binding motif two immunotyrosine 
inhibitory motif – immunotyrosine-based switch motif (ITIM/ITSM) tandems. 
These motifs are commonly found in the intracellular domain of inhibitory 
immune receptors. In vitro phosphorylation with the c-Src kinase and 
subsequent mapping by mass spectrometry analysis indicated that c-Src 
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tyrosine-phosphorylates the Csk-binding site and both ITIMs of BepE. No 
phosphorylation of an ITSM could be detected, which might be due to the fact 
that another kinase phosphorylates these motifs in vivo. Both the inhibitory 
immune receptors and BepE do contain ITIMs, ITSMs, Csk-binding sites, localize 
to the plasma membrane, are tyrosine-phosphorylated by Src family kinases and 
bind SHP2 and Csk. Additionally, BepE is constitutively tyrosine-phosphorylated 
in HEK293T cells as well as in the primary HUVECs (Chapter 3.2), in contrast to 
most inhibitory immune receptors, which are thought to only become 
phosphorylated upon engagement of their extracellular ligands. All these lines of 
evidence indicate BepE mimicking inhibitory immune receptors.  
Csk contains one SH2 domain, SHP2 two. To elucidate the binding sites of these 
two proteins, and also to be able to use mutants lacking these interactions, we 
generated a panel of tyrosine-to-phenylalanine exchange mutants in BepE.  
While Csk binds to one motif (the one with the similarity to the Csk-binding site 
of VE-Cadherin), SHP2 interacts with motifs in the two ITIM-ITSM tandems. 
While this interaction study was carried out in HEK293T cells, more potential 
ITIM/ITSM-binding proteins such as SHP-1 and SHIP, EAT-2 and SAP might 
increase the complexity of the picture in myeloid and lymphoid cells. The two 
adapter proteins SAP and EAT-2 have been shown to bind to ITSMs. While some 
cells such as NK express both adapters, other cells as for example T-cell do only 
express SAP, and other such as DCs only EAT-2. While SAP recruits Fyn and can 
lead to an increase in cell activation, EAT-2 recruits phosphatases and Csk, 
inhibiting the activity. For BepE, this opens the possibility of switching its mode 
of action, depending on the cell type it is translocated into.  
Collaborations have been initiated to assess the immunomodulatory potential of 
BepE and we are currently studying the impact of this protein in our HUVEC 
models. 
 
 
To summarize, my Ph.D. thesis aimed at investigating the VirB/VirD4 T4SS of 
Bartonella henselae for the presence of secreted substrates and signals mediating 
this secretion. Additionally, to describe the functions and interaction partners of 
these substrates in the host cell, with an emphasis on the putative tyrosine-
phosphorylated effectors. . The core findings of this thesis are a.) The discovery 
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of seven modular substrates secreted by the apparatus b.) Description of the BID 
domain mediating the secretion of proteins and protein-DNA complexes, c.) Csk 
and SHP2 being interaction partners for BepD and BepE on the host cell side d.) 
BepE mimicking inhibitory immune receptors. 
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6. Outlook 
 
Although we have now some understanding concerning the secretion 
requirements, the description of which parts of the Beps play a role in secretion, 
as effectors in cells, or in both, is still incomplete. Deepening this understanding 
will be of critical importance to further study the role of the VirB/VirD4 secretion 
apparatus in the pathogenesis of Bartonellae infections. 
Describing interaction partners and putative kinases for BepD and F opened the 
door for future studies, and first exciting results concerning the role of BepD 
have already been acquired using constructs and mutants described here.  
For BepE, sound foundations have been laid out to unravel its functions.  
Adequate models exist and are currently being used for studying the putative 
impact of this protein on the endothelium. The assessment of it 
immunomodulatory potential poses a tremendous challenge, and will not come 
to completion without an adequate animal model, as the publication history of 
studying the immune inhibitory receptors shows. Nevertheless, insights on how 
highly adapted bacteria do modulate our defense lines will be well worth the 
investments, and may shed light on human diseases previously not connected to 
pathogens. 
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